

CLAIMS

We claim:

1. A multifunctional molecule, comprising:
 - (a) a first antigen binding domain that binds to a T cell receptor beta chain constant domain 2 (TRBC~~2~~), and
 - (b) a second antigen binding domain that binds to NKp30,wherein the TRBC is T cell receptor beta chain constant domain 1 (TRBC1) or T cell receptor beta chain constant domain 2 (TRBC2), and
wherein:
 - (A) when the TRBC is TRBC1, the first antigen binding domain comprises:
 - (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1), a heavy chain complementarity determining region 2 (VHCDR2), and a heavy chain complementarity determining region 3 (VHCDR3) that comprise the sequences of SEQ ID NO: 8517, SEQ ID NO: 7355, and SEQ ID NO: 202, respectively, or the sequences of SEQ ID NO: 200, SEQ ID NO: 7355, and SEQ ID NO: 202, respectively; and/or
 - (ii) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1), a light chain complementarity determining region 2 (VLCDR2), and a light chain complementarity determining region 3 (VLCDR3) that comprise the sequences of: SEQ ID NO: 223, SEQ ID NO: 224, and SEQ ID NO: 8210, respectively; SEQ ID NO: 8673, SEQ ID NO: 224, and SEQ ID NO: 8674, respectively; SEQ ID NO: 8676, SEQ ID NO: 224, and SEQ ID NO: 8674, respectively; SEQ ID NO: 8677, SEQ ID NO: 224, and SEQ ID NO: 225, respectively; SEQ ID NO: 8678, SEQ ID NO: 224, and SEQ ID NO: 225, respectively; SEQ ID NO: 8679, SEQ ID NO: 224, and SEQ ID NO: 225, respectively; or SEQ ID NO: 8680, SEQ ID NO: 224, and SEQ ID NO: 225, respectively; and
 - (B) when the TRBC is TRBC2, the first antigen binding domain comprises:
 - (1)(i) a VH comprising a VHCDR1, a VHCDR2, and a VHCDR3 that comprise the sequences of:
—
SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8285, respectively; SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8296, respectively; SEQ ID NO: 7394, SEQ ID NO: 201, and SEQ ID NO: 7396, respectively; SEQ ID NO: 7346, SEQ ID NO: 201, and SEQ ID NO: 7398, respectively; SEQ ID NO: 7346, SEQ ID NO: 201, and SEQ ID NO: 7400, respectively; SEQ ID NO: 7401, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively; SEQ ID NO: 7405, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively; SEQ ID NO: 7407, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;

SEQ ID NO: 7422, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 7427, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 7430, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 7401, SEQ ID NO: 8260, and SEQ ID NO: 8043, respectively;
SEQ ID NO: 7401, SEQ ID NO: 8044, and SEQ ID NO: 8045, respectively;
SEQ ID NO: 7401, SEQ ID NO: 8044, and SEQ ID NO: 8046, respectively;
SEQ ID NO: 7401, SEQ ID NO: 8044, and SEQ ID NO: 8047, respectively;
SEQ ID NO: 8041, SEQ ID NO: 8260, and SEQ ID NO: 8043, respectively;
SEQ ID NO: 8041, SEQ ID NO: 8044, and SEQ ID NO: 8045, respectively;
SEQ ID NO: 8041, SEQ ID NO: 8044, and SEQ ID NO: 8046, respectively;
SEQ ID NO: 8041, SEQ ID NO: 8044, and SEQ ID NO: 8047, respectively;
SEQ ID NO: 8529, SEQ ID NO: 201, and SEQ ID NO: 7396, respectively;
SEQ ID NO: 8531, SEQ ID NO: 201, and SEQ ID NO: 7398, respectively;
SEQ ID NO: 8533, SEQ ID NO: 201, and SEQ ID NO: 7400, respectively;
SEQ ID NO: 8535, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 8537, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 8539, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 8541, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 8543, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 8545, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 8547, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 8549, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 8551, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 8272, SEQ ID NO: 8260, and SEQ ID NO: 8043, respectively;
SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8045, respectively;
SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8046, respectively; or
SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8047, respectively; and/or
(ii) a VL comprising a VLCDR1, a VLCDR2, and a VLCDR3 that comprise the sequences of:
SEQ ID NO: 8051, SEQ ID NO: 8049, and SEQ ID NO: 8052, respectively;
SEQ ID NO: 7409, SEQ ID NO: 224, and SEQ ID NO: 225, respectively;
SEQ ID NO: 7410, SEQ ID NO: 224, and SEQ ID NO: 225, respectively; or
SEQ ID NO: 8048, SEQ ID NO: 8049, and SEQ ID NO: 8050, respectively; or
(2) a VH and a VL respectively comprising a VHCDR1, a VHCDR2, and a VHCDR3; and a
VLCDR1, a VLCDR2, and a VLCDR3 that comprise the VHCDR1, VHCDR2, and VHCDR3
sequences, and the VLCDR1, VLCDR2, and VLCDR3 sequences of:
SEQ ID NO: 8059, and SEQ ID NO: 8060, respectively;

SEQ	ID	NO:	8061,	and	SEQ	ID	NO:	8062,	respectively;	
SEQ	ID	NO:	8063,	and	SEQ	ID	NO:	8064,	respectively;	
SEQ	ID	NO:	8065,	and	SEQ	ID	NO:	8066,	respectively;	
SEQ	ID	NO:	8067,	and	SEQ	ID	NO:	8068,	respectively;	
SEQ	ID	NO:	8069,	and	SEQ	ID	NO:	8070,	respectively;	
SEQ	ID	NO:	8071,	and	SEQ	ID	NO:	8072,	respectively;	
SEQ	ID	NO:	8073,	and	SEQ	ID	NO:	8074,	respectively;	
SEQ	ID	NO:	8075,	and	SEQ	ID	NO:	8076,	respectively;	
SEQ	ID	NO:	8077,	and	SEQ	ID	NO:	8078,	respectively;	
SEQ	ID	NO:	8079,	and	SEQ	ID	NO:	8080,	respectively;	
SEQ	ID	NO:	8081,	and	SEQ	ID	NO:	8670,	respectively;	
SEQ	ID	NO:	8082,	and	SEQ	ID	NO:	8083,	respectively;	
SEQ	ID	NO:	8084,	and	SEQ	ID	NO:	8085,	respectively;	
SEQ	ID	NO:	8086	,	and	SEQ	ID	NO:	8087,	respectively;
SEQ	ID	NO:	8088,	and	SEQ	ID	NO:	8089,	respectively;	
SEQ	ID	NO:	8090,	and	SEQ	ID	NO:	8091,	respectively;	
SEQ	ID	NO:	8092,	and	SEQ	ID	NO:	8093,	respectively;	
SEQ	ID	NO:	8094,	and	SEQ	ID	NO:	8095,	respectively;	
SEQ	ID	NO:	8096,	and	SEQ	ID	NO:	8097,	respectively;	
SEQ	ID	NO:	8098,	and	SEQ	ID	NO:	8099,	respectively;	
SEQ	ID	NO:	8100,	and	SEQ	ID	NO:	8101,	respectively;	
SEQ	ID	NO:	8102,	and	SEQ	ID	NO:	8103,	respectively;	
SEQ	ID	NO:	8104,	and	SEQ	ID	NO:	8105,	respectively;	
SEQ	ID	NO:	8106,	and	SEQ	ID	NO:	8107,	respectively;	
SEQ	ID	NO:	8108,	and	SEQ	ID	NO:	8109,	respectively;	
SEQ	ID	NO:	8110,	and	SEQ	ID	NO:	8112,	respectively;	
SEQ	ID	NO:	8113,	and	SEQ	ID	NO:	8114,	respectively;	
SEQ	ID	NO:	8115,	and	SEQ	ID	NO:	8116,	respectively;	
SEQ	ID	NO:	8117,	and	SEQ	ID	NO:	8118,	respectively;	
SEQ	ID	NO:	8119,	and	SEQ	ID	NO:	8120,	respectively;	
SEQ	ID	NO:	8121,	and	SEQ	ID	NO:	8122,	respectively;	
SEQ	ID	NO:	8123,	and	SEQ	ID	NO:	8124,	respectively;	
SEQ	ID	NO:	8125,	and	SEQ	ID	NO:	8126,	respectively;	
SEQ	ID	NO:	8127,	and	SEQ	ID	NO:	8128,	respectively;	
SEQ	ID	NO:	8129,	and	SEQ	ID	NO:	8130,	respectively;	
SEQ	ID	NO:	8131,	and	SEQ	ID	NO:	8132,	respectively;	

SEQ	ID	NO:	8133,	and	SEQ	ID	NO:	8134,	respectively;
SEQ	ID	NO:	8135,	and	SEQ	ID	NO:	8136,	respectively;
SEQ	ID	NO:	8137,	and	SEQ	ID	NO:	8138,	respectively;
SEQ	ID	NO:	8139,	and	SEQ	ID	NO:	8140,	respectively;
SEQ	ID	NO:	8141,	and	SEQ	ID	NO:	8142,	respectively;
SEQ	ID	NO:	8143,	and	SEQ	ID	NO:	8144,	respectively;
SEQ	ID	NO:	8145,	and	SEQ	ID	NO:	8146,	respectively;
SEQ	ID	NO:	8147,	and	SEQ	ID	NO:	8148,	respectively;
SEQ	ID	NO:	8149,	and	SEQ	ID	NO:	8150,	respectively;
SEQ	ID	NO:	8151,	and	SEQ	ID	NO:	8152,	respectively;
SEQ	ID	NO:	8153,	and	SEQ	ID	NO:	8154,	respectively;
SEQ	ID	NO:	8155,	and	SEQ	ID	NO:	8156,	respectively;
SEQ	ID	NO:	8157,	and	SEQ	ID	NO:	8158,	respectively;
SEQ	ID	NO:	8159,	and	SEQ	ID	NO:	8160,	respectively;
SEQ	ID	NO:	8161,	and	SEQ	ID	NO:	8162,	respectively;
SEQ	ID	NO:	8163,	and	SEQ	ID	NO:	8164,	respectively;
SEQ	ID	NO:	8165,	and	SEQ	ID	NO:	8166,	respectively;
SEQ	ID	NO:	8167,	and	SEQ	ID	NO:	8168,	respectively;
SEQ	ID	NO:	8169,	and	SEQ	ID	NO:	8170,	respectively;
SEQ	ID	NO:	8171,	and	SEQ	ID	NO:	8172,	respectively;
SEQ	ID	NO:	8173,	and	SEQ	ID	NO:	8174,	respectively;
SEQ	ID	NO:	8175,	and	SEQ	ID	NO:	8176,	respectively;
SEQ	ID	NO:	8177,	and	SEQ	ID	NO:	8178,	respectively;
SEQ	ID	NO:	8179,	and	SEQ	ID	NO:	8180,	respectively;
SEQ	ID	NO:	8181,	and	SEQ	ID	NO:	8182,	respectively;
SEQ	ID	NO:	8183,	and	SEQ	ID	NO:	8184,	respectively;
SEQ	ID	NO:	8185,	and	SEQ	ID	NO:	8186,	respectively;
SEQ	ID	NO:	8187,	and	SEQ	ID	NO:	8188,	respectively;
SEQ	ID	NO:	8189,	and	SEQ	ID	NO:	8190,	respectively;
SEQ	ID	NO:	8191,	and	SEQ	ID	NO:	8192,	respectively;
SEQ	ID	NO:	8193,	and	SEQ	ID	NO:	8194,	respectively;
SEQ	ID	NO:	8195,	and	SEQ	ID	NO:	8196,	respectively;
SEQ	ID	NO:	8197,	and	SEQ	ID	NO:	8198,	respectively;
SEQ	ID	NO:	8199,	and	SEQ	ID	NO:	8200,	respectively;
SEQ	ID	NO:	8201,	and	SEQ	ID	NO:	8202,	respectively;
SEQ	ID	NO:	8011,	and	SEQ	ID	NO:	8012,	respectively;

~~SEQ ID NO: 8203, and SEQ ID NO: 8204, respectively; or
SEQ ID NO: 8205, and SEQ ID NO: 8206, respectively.
first antigen binding domain comprises one or more CDRs, framework regions, variable regions, or
antigen binding domains disclosed in any of Table 9A or Table 9B, Table 10, Table 11, Table 12,
Table 13, Table 14, Table 15 and Table 17 and Table 39, or a sequence having at least 85%, 90%,
95%, or 99% identity thereto.~~

2. The multifunctional molecule of claim 1, wherein the TRBC is TRBC1, and the first antigen binding domain comprises:

~~(i) the~~ VH comprising a ~~heavy chain complementarity determining region 1 (VHCDR1)~~, a VHCDR2, and a VHCDR3 ~~that comprise the sequences of SEQ ID NO: 8517, SEQ ID NO: 7355, and SEQ ID NO: 202, respectively, or the sequences of SEQ ID NO: 200, SEQ ID NO: 7355, and~~
~~SEQ ID NO: 202, respectively;~~ and

~~(ii) the~~ VL comprising a ~~light chain complementarity determining region 1 (VLCDR1)~~, a VLCDR2, and a VLCDR3 ~~that comprise the sequences of:~~
~~SEQ ID NO: 223, SEQ ID NO: 224, and SEQ ID NO: 8210, respectively;
SEQ ID NO: 8673, SEQ ID NO: 224, and SEQ ID NO: 8674, respectively;
SEQ ID NO: 8676, SEQ ID NO: 224, and SEQ ID NO: 8674, respectively;
SEQ ID NO: 8677, SEQ ID NO: 224, and SEQ ID NO: 225, respectively;
SEQ ID NO: 8678, SEQ ID NO: 224, and SEQ ID NO: 225, respectively;
SEQ ID NO: 8679, SEQ ID NO: 224, and SEQ ID NO: 225, respectively; or
SEQ ID NO: 8680, SEQ ID NO: 224, and SEQ ID NO: 225, respectively, wherein the VHCDR1, VHCDR2, and VHCDR3 comprise the amino acid sequences of SEQ ID NOs: 7441, 201, and 7442, respectively; or the VLCDR1, VLCDR2, and VLCDR3 comprise the amino acid sequences of SEQ ID NOs: 7443, 224, and 225, respectively.~~

3. The multifunctional molecule of claim 1 or 2, wherein the TRBC is TRBC1, and the first antigen binding domain comprises:

~~(i) a VH comprising a sequence having at least 85% identity to the sequence of SEQ ID NO: 8304 or the sequence of SEQ ID NO: 7351, and/or~~

~~(ii) a VL comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 258, SEQ ID NO: 8681, SEQ ID NO: 8682, SEQ ID NO: 8683, SEQ ID NO: 8684, SEQ ID NO: 8685, and SEQ ID NO: 8686,~~

~~optionally, wherein the VL comprises any one sequence selected from the group consisting of SEQ ID NO: 258, SEQ ID NO: 8681, SEQ ID NO: 8682, SEQ ID NO: 8683, SEQ ID NO: 8684, SEQ ID NO: 8685, and SEQ ID NO: 8686~~
~~VHCDR1, VHCDR2, and VHCDR3 comprise the amino acid sequences of:~~

~~SEQ ID NOs: 7422, 201, and 7403, respectively;~~

~~SEQ ID NOs: 7401, 201, and 7403, respectively;~~
~~SEQ ID NOs: 7394, 201, and 7396, respectively;~~
~~SEQ ID NOs: 7346, 201, and 7398, respectively;~~
~~SEQ ID NOs: 7346, 201, and 7400, respectively;~~
~~SEQ ID NOs: 7405, 201, and 7403, respectively;~~
~~SEQ ID NOs: 7407, 201, and 7403, respectively;~~
~~SEQ ID NOs: 7427, 201, and 7403, respectively; or~~
~~SEQ ID NOs: 7430, 201, and 7403, respectively.~~

4. The multifunctional molecule of any one of claims 1-2 or 3, wherein the TRBC is TRBC1, and the first antigen binding domain comprises VLCDR1, VLCDR2, and VLCDR3 ~~comprise the amino acid sequences of:~~
 - (i) a VH comprising a sequence having at least 85% identity to the sequence of SEQ ID NO: 8304 or the sequence of SEQ ID NO: 7351,
~~optionally, wherein the VH comprises the sequence of SEQ ID NO: 8304 or the sequence of SEQ ID NO: 7351; and~~
 - (ii) a VL comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 258, SEQ ID NO: 8681, SEQ ID NO: 8682, SEQ ID NO: 8683, SEQ ID NO: 8684, SEQ ID NO: 8685, and SEQ ID NO: 8686,
~~optionally, wherein the VL comprises any one sequence selected from the group consisting of SEQ ID NO: 258, SEQ ID NO: 8681, SEQ ID NO: 8682, SEQ ID NO: 8683, SEQ ID NO: 8684, SEQ ID NO: 8685, and SEQ ID NO: 8686~~

~~SEQ ID NOs: 7410, 224, and 225, respectively; or~~
~~SEQ ID NOs: 7409, 224, and 225, respectively.~~
5. The multifunctional molecule of any of claims 1-4, wherein the TRBC is TRBC2, and the first antigen binding domain comprises VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 ~~comprise the amino acid sequences of:~~
 - (i) the VH comprising a VHCDR1, a VHCDR2, and a VHCDR3 that comprise the sequences of:
SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8285, respectively;
SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8296, respectively;
SEQ ID NO: 7394, SEQ ID NO: 201, and SEQ ID NO: 7396, respectively;
SEQ ID NO: 7346, SEQ ID NO: 201, and SEQ ID NO: 7398, respectively;
SEQ ID NO: 7346, SEQ ID NO: 201, and SEQ ID NO: 7400, respectively;
SEQ ID NO: 7401, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 7405, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 7407, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;
SEQ ID NO: 7422, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;

~~SEQ ID NO: 7427, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 7430, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 7401, SEQ ID NO: 8260, and SEQ ID NO: 8043, respectively;~~
~~SEQ ID NO: 7401, SEQ ID NO: 8044, and SEQ ID NO: 8045, respectively;~~
~~SEQ ID NO: 7401, SEQ ID NO: 8044, and SEQ ID NO: 8046, respectively;~~
~~SEQ ID NO: 7401, SEQ ID NO: 8044, and SEQ ID NO: 8047, respectively;~~
~~SEQ ID NO: 8041, SEQ ID NO: 8260, and SEQ ID NO: 8043, respectively;~~
~~SEQ ID NO: 8041, SEQ ID NO: 8044, and SEQ ID NO: 8045, respectively;~~
~~SEQ ID NO: 8041, SEQ ID NO: 8044, and SEQ ID NO: 8046, respectively;~~
~~SEQ ID NO: 8041, SEQ ID NO: 8044, and SEQ ID NO: 8047, respectively;~~
~~SEQ ID NO: 8529, SEQ ID NO: 201, and SEQ ID NO: 7396, respectively;~~
~~SEQ ID NO: 8531, SEQ ID NO: 201, and SEQ ID NO: 7398, respectively;~~
~~SEQ ID NO: 8533, SEQ ID NO: 201, and SEQ ID NO: 7400, respectively;~~
~~SEQ ID NO: 8535, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 8537, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 8539, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 8541, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 8543, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 8545, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 8547, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 8549, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 8551, SEQ ID NO: 201, and SEQ ID NO: 7403, respectively;~~
~~SEQ ID NO: 8272, SEQ ID NO: 8260, and SEQ ID NO: 8043, respectively;~~
~~SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8045, respectively;~~
~~SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8046, respectively; or~~
~~SEQ ID NO: 8272, SEQ ID NO: 8044, and SEQ ID NO: 8047, respectively; and~~
(ii) the VL comprising a VLCDR1, a VLCDR2, and a VLCDR3 that comprise the sequences of:
~~SEQ ID NO: 8051, SEQ ID NO: 8049, and SEQ ID NO: 8052, respectively;~~
~~SEQ ID NO: 7409, SEQ ID NO: 224, and SEQ ID NO: 225, respectively;~~
~~SEQ ID NO: 7410, SEQ ID NO: 224, and SEQ ID NO: 225, respectively; or~~
~~SEQ ID NO: 8048, SEQ ID NO: 8049, and SEQ ID NO: 8050, respectively~~~~SEQ ID NOs: 7422, 201, 7403,~~
~~7410, 224, and 225, respectively;~~

~~SEQ ID NOs: 7401, 201, 7403, 7410, 224, and 225, respectively;~~

~~SEQ ID NOs: 7394, 201, 7396, 7410, 224, and 225, respectively;~~

~~SEQ ID NOs: 7346, 201, 7398, 7410, 224, and 225, respectively;~~

~~SEQ ID NOs: 7346, 201, 7400, 7410, 224, and 225, respectively;~~

~~SEQ ID NOs: 7405, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7407, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7427, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7430, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7422, 201, 7403, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7401, 201, 7403, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7394, 201, 7396, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7346, 201, 7398, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7346, 201, 7400, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7405, 201, 7403, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7407, 201, 7403, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7427, 201, 7403, 7409, 224, and 225, respectively; or~~
~~SEQ ID NOs: 7430, 201, 7403, 7409, 224, and 225, respectively.~~

6. The multifunctional molecule of ~~any of claims 1 or 2-5~~, wherein the ~~TRBC is TRBC2, and the first~~ antigen binding domain comprises a VH and a VL respectively comprising a VHCDR1, a VHCDR2, and a VHCDR3; and a VLCDR1, a VLCDR2, and a VLCDR3 that comprise the sequences of:
~~SEQ ID NOs: 7422, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7401, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7394, 201, 7396, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7346, 201, 7398, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7346, 201, 7400, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7405, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7407, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7427, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7430, 201, 7403, 7410, 224, and 225, respectively;~~
~~SEQ ID NOs: 7422, 201, 7403, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7401, 201, 7403, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7394, 201, 7396, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7346, 201, 7398, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7346, 201, 7400, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7405, 201, 7403, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7407, 201, 7403, 7409, 224, and 225, respectively;~~
~~SEQ ID NOs: 7427, 201, 7403, 7409, 224, and 225, respectively; or~~
~~SEQ ID NOs: 7430, 201, 7403, 7409, 224, and 225, respectively.~~ ~~VH comprises an amino acid~~ sequence selected from the group consisting of ~~SEQ ID NOs: 7420, 7423, 7411, 7412, 7413, 7414, 7415, 7416, 7417, 7425, 7428, and 7431 (or a sequence having at least 85%, 90%, 95%, or 99%~~

identity thereto) and/or the VL comprises an amino acid sequence selected from the group consisting of ~~SEQ ID NOs: 7419 and 7418~~ (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto).

7. The multifunctional molecule of any of claims ~~1, 5, 2-~~ and 6, wherein the ~~TRBC is TRBC2, and the first antigen binding domain comprises~~ VH and VL ~~comprise the amino acid sequences of:~~

~~(1)(i) a VH comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 8284, SEQ ID NO: 8295, SEQ ID NO: 7411, SEQ ID NO: 7412, SEQ ID NO: 7413, SEQ ID NO: 7414, SEQ ID NO: 7415, SEQ ID NO: 7416, SEQ ID NO: 7417, SEQ ID NO: 7420, SEQ ID NO: 7423, SEQ ID NO: 7425, SEQ ID NO: 7428, SEQ ID NO: 7431, SEQ ID NO: 8011, SEQ ID NO: 8013, SEQ ID NO: 8020, and SEQ ID NO: 8022; and/or (ii) a VL comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 8282, SEQ ID NO: 8293, SEQ ID NO: 7418, SEQ ID NO: 7419, SEQ ID NO: 8012, SEQ ID NO: 8014, SEQ ID NO: 8021, and SEQ ID NO: 8023; or~~

~~(2) a VH and a VL comprising sequences having at least 85% identity to the sequences of:~~

~~SEQ~~	~~ID~~	~~NO:~~	~~7420,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7423,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7411,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7412,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7413,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7414,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7415,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7416,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7417,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7425,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7428,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7431,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7419,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7420,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7423,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7411,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7412,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7413,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7414,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7415,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7416,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7417,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~
~~SEQ~~	~~ID~~	~~NO:~~	~~7425,~~	~~and~~	~~SEQ~~	~~ID~~	~~NO:~~	~~7418,~~	~~respectively;~~

SEQ	ID	NO:	7428,	and	SEQ	ID	NO:	7418,	respectively;	
SEQ	ID	NO:	7431,	and	SEQ	ID	NO:	7418,	respectively;	
SEQ	ID	NO:	8059,	and	SEQ	ID	NO:	8060,	respectively;	
SEQ	ID	NO:	8061,	and	SEQ	ID	NO:	8062,	respectively;	
SEQ	ID	NO:	8063,	and	SEQ	ID	NO:	8064,	respectively;	
SEQ	ID	NO:	8065,	and	SEQ	ID	NO:	8066,	respectively;	
SEQ	ID	NO:	8067,	and	SEQ	ID	NO:	8068,	respectively;	
SEQ	ID	NO:	8069,	and	SEQ	ID	NO:	8070,	respectively;	
SEQ	ID	NO:	8071,	and	SEQ	ID	NO:	8072,	respectively;	
SEQ	ID	NO:	8073,	and	SEQ	ID	NO:	8074,	respectively;	
SEQ	ID	NO:	8075,	and	SEQ	ID	NO:	8076,	respectively;	
SEQ	ID	NO:	8077,	and	SEQ	ID	NO:	8078,	respectively;	
SEQ	ID	NO:	8079,	and	SEQ	ID	NO:	8080,	respectively;	
SEQ	ID	NO:	8081,	and	SEQ	ID	NO:	8670,	respectively;	
SEQ	ID	NO:	8082,	and	SEQ	ID	NO:	8083,	respectively;	
SEQ	ID	NO:	8084,	and	SEQ	ID	NO:	8085,	respectively;	
SEQ	ID	NO:	8086	,	and	SEQ	ID	NO:	8087,	respectively;
SEQ	ID	NO:	8088,	and	SEQ	ID	NO:	8089,	respectively;	
SEQ	ID	NO:	8090,	and	SEQ	ID	NO:	8091,	respectively;	
SEQ	ID	NO:	8092,	and	SEQ	ID	NO:	8093,	respectively;	
SEQ	ID	NO:	8094,	and	SEQ	ID	NO:	8095,	respectively;	
SEQ	ID	NO:	8096,	and	SEQ	ID	NO:	8097,	respectively;	
SEQ	ID	NO:	8098,	and	SEQ	ID	NO:	8099,	respectively;	
SEQ	ID	NO:	8100,	and	SEQ	ID	NO:	8101,	respectively;	
SEQ	ID	NO:	8102,	and	SEQ	ID	NO:	8103,	respectively;	
SEQ	ID	NO:	8104,	and	SEQ	ID	NO:	8105,	respectively;	
SEQ	ID	NO:	8106,	and	SEQ	ID	NO:	8107,	respectively;	
SEQ	ID	NO:	8108,	and	SEQ	ID	NO:	8109,	respectively;	
SEQ	ID	NO:	8110,	and	SEQ	ID	NO:	8112,	respectively;	
SEQ	ID	NO:	8113,	and	SEQ	ID	NO:	8114,	respectively;	
SEQ	ID	NO:	8115,	and	SEQ	ID	NO:	8116,	respectively;	
SEQ	ID	NO:	8117,	and	SEQ	ID	NO:	8118,	respectively;	
SEQ	ID	NO:	8119,	and	SEQ	ID	NO:	8120,	respectively;	
SEQ	ID	NO:	8121,	and	SEQ	ID	NO:	8122,	respectively;	
SEQ	ID	NO:	8123,	and	SEQ	ID	NO:	8124,	respectively;	
SEQ	ID	NO:	8125,	and	SEQ	ID	NO:	8126,	respectively;	

SEQ	ID	NO:	8127,	and	SEQ	ID	NO:	8128,	respectively;
SEQ	ID	NO:	8129,	and	SEQ	ID	NO:	8130,	respectively;
SEQ	ID	NO:	8131,	and	SEQ	ID	NO:	8132,	respectively;
SEQ	ID	NO:	8133,	and	SEQ	ID	NO:	8134,	respectively;
SEQ	ID	NO:	8135,	and	SEQ	ID	NO:	8136,	respectively;
SEQ	ID	NO:	8137,	and	SEQ	ID	NO:	8138,	respectively;
SEQ	ID	NO:	8139,	and	SEQ	ID	NO:	8140,	respectively;
SEQ	ID	NO:	8141,	and	SEQ	ID	NO:	8142,	respectively;
SEQ	ID	NO:	8143,	and	SEQ	ID	NO:	8144,	respectively;
SEQ	ID	NO:	8145,	and	SEQ	ID	NO:	8146,	respectively;
SEQ	ID	NO:	8147,	and	SEQ	ID	NO:	8148,	respectively;
SEQ	ID	NO:	8149,	and	SEQ	ID	NO:	8150,	respectively;
SEQ	ID	NO:	8151,	and	SEQ	ID	NO:	8152,	respectively;
SEQ	ID	NO:	8153,	and	SEQ	ID	NO:	8154,	respectively;
SEQ	ID	NO:	8155,	and	SEQ	ID	NO:	8156,	respectively;
SEQ	ID	NO:	8157,	and	SEQ	ID	NO:	8158,	respectively;
SEQ	ID	NO:	8159,	and	SEQ	ID	NO:	8160,	respectively;
SEQ	ID	NO:	8161,	and	SEQ	ID	NO:	8162,	respectively;
SEQ	ID	NO:	8163,	and	SEQ	ID	NO:	8164,	respectively;
SEQ	ID	NO:	8165,	and	SEQ	ID	NO:	8166,	respectively;
SEQ	ID	NO:	8167,	and	SEQ	ID	NO:	8168,	respectively;
SEQ	ID	NO:	8169,	and	SEQ	ID	NO:	8170,	respectively;
SEQ	ID	NO:	8171,	and	SEQ	ID	NO:	8172,	respectively;
SEQ	ID	NO:	8173,	and	SEQ	ID	NO:	8174,	respectively;
SEQ	ID	NO:	8175,	and	SEQ	ID	NO:	8176,	respectively;
SEQ	ID	NO:	8177,	and	SEQ	ID	NO:	8178,	respectively;
SEQ	ID	NO:	8179,	and	SEQ	ID	NO:	8180,	respectively;
SEQ	ID	NO:	8181,	and	SEQ	ID	NO:	8182,	respectively;
SEQ	ID	NO:	8183,	and	SEQ	ID	NO:	8184,	respectively;
SEQ	ID	NO:	8185,	and	SEQ	ID	NO:	8186,	respectively;
SEQ	ID	NO:	8187,	and	SEQ	ID	NO:	8188,	respectively;
SEQ	ID	NO:	8189,	and	SEQ	ID	NO:	8190,	respectively;
SEQ	ID	NO:	8191,	and	SEQ	ID	NO:	8192,	respectively;
SEQ	ID	NO:	8193,	and	SEQ	ID	NO:	8194,	respectively;
SEQ	ID	NO:	8195,	and	SEQ	ID	NO:	8196,	respectively;
SEQ	ID	NO:	8197,	and	SEQ	ID	NO:	8198,	respectively;

SEQ ID NO: 8199, and SEQ ID NO: 8200, respectively;
SEQ ID NO: 8201, and SEQ ID NO: 8202, respectively;
SEQ ID NO: 8203, and SEQ ID NO: 8204, respectively;
SEQ ID NO: 8011, and SEQ ID NO: 8012, respectively; or
SEQ ID NO: 8205, and SEQ ID NO: 8206, respectively

~~SEQ ID NOs: 7420 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7423 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7411 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7412 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7413 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7414 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7415 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7416 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7417 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7425 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7428 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7431 and 7419, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7420 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7423 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7411 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7412 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7413 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7414 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7415 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7416 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7417 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7425 and 7418, respectively (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~

~~SEQ ID NOs: 7428 and 7418, respectively or a sequence having at least 85%, 90%, 95%, or 99% identity thereto;~~

~~SEQ ID NOs: 7431 and 7418, respectively or a sequence having at least 85%, 90%, 95%, or 99% identity thereto.~~

8. The multifunctional molecule of any one of claims 1 and 51-7, wherein the TRBC is TRBC2, and the first antigen binding domain comprises:

(i) the VH comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 8284, SEQ ID NO: 8295, SEQ ID NO: 7411, SEQ ID NO: 7412, SEQ ID NO: 7413, SEQ ID NO: 7414, SEQ ID NO: 7415, SEQ ID NO: 7416, SEQ ID NO: 7417, SEQ ID NO: 7420, SEQ ID NO: 7423, SEQ ID NO: 7425, SEQ ID NO: 7428, SEQ ID NO: 7431, SEQ ID NO: 8011, SEQ ID NO: 8013, SEQ ID NO: 8020, and SEQ ID NO: 8022~~the first antigen binding domain has a higher affinity for a T cell receptor comprising TRBC2 than for a T cell receptor not comprising TRBC2, optionally wherein the KD for the binding between the first antigen binding domain and TRBC2 is no more than 40%, 30%, 20%, 10%, 1%, 0.1%, or 0.01% of the KD for the binding between the first antigen binding domain and a T cell receptor not comprising TRBC2; and~~

(ii) the VL comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 8282, SEQ ID NO: 8293, SEQ ID NO: 7418, SEQ ID NO: 7419, SEQ ID NO: 8012, SEQ ID NO: 8014, SEQ ID NO: 8021, and SEQ ID NO: 8023~~first antigen binding domain has a higher affinity for a T cell receptor comprising TRBC2 than for a T cell receptor comprising TRBC1, optionally wherein the KD for the binding between the first antigen binding domain and TRBC2 is no more than 40%, 30%, 20%, 10%, 1%, 0.1%, or 0.01% of the KD~~

~~for the binding between the first antigen binding domain and a T cell receptor not comprising TRBC1; or~~

~~(iii) binding of the first antigen binding domain to TRBC2 on a lymphoma cell or lymphocyte, e.g., T cell, does not appreciably activate the lymphoma cell or lymphocyte, e.g., T cell, e.g., as measured by T cell proliferation, expression of a T cell activation marker (e.g., CD69 or CD25), and/or expression of a cytokine (e.g., TNF α and IFN γ).~~

9. The multifunctional molecule of any one of claims 1 and 54-8, wherein the TRBC is TRBC2, and the first antigen binding domain comprises:

(1)(i) a VH comprising any one sequence selected from the group consisting of SEQ ID NO: 8284, SEQ ID NO: 8295, SEQ ID NO: 7411, SEQ ID NO: 7412, SEQ ID NO: 7413, SEQ ID NO: 7414, SEQ ID NO: 7415, SEQ ID NO: 7416, SEQ ID NO: 7417, SEQ ID NO: 7420, SEQ ID NO: 7423, SEQ ID NO: 7425, SEQ ID NO: 7428, SEQ ID NO: 7431, SEQ ID NO: 8011, SEQ ID NO: 8013, SEQ ID NO: 8020, and SEQ ID NO: 8022; and/or

(ii) a VL comprising any one sequence selected from the group consisting of SEQ ID NO: 8282, SEQ ID NO: 8293, SEQ ID NO: 7418, SEQ ID NO: 7419, SEQ ID NO: 8012, SEQ ID NO: 8014, SEQ ID NO: 8021, and SEQ ID NO: 8023; or

(2) a VH and a VL comprising the sequences of:
SEQ ID NO: 7420, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7423, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7411, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7412, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7413, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7414, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7415, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7416, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7417, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7425, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7428, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7431, and SEQ ID NO: 7419, respectively;
SEQ ID NO: 7420, and SEQ ID NO: 7418, respectively;
SEQ ID NO: 7423, and SEQ ID NO: 7418, respectively;
SEQ ID NO: 7411, and SEQ ID NO: 7418, respectively;
SEQ ID NO: 7412, and SEQ ID NO: 7418, respectively;
SEQ ID NO: 7413, and SEQ ID NO: 7418, respectively;
SEQ ID NO: 7414, and SEQ ID NO: 7418, respectively;
SEQ ID NO: 7415, and SEQ ID NO: 7418, respectively;

SEQ	ID	NO:	7416,	and	SEQ	ID	NO:	7418,	respectively;	
SEQ	ID	NO:	7417,	and	SEQ	ID	NO:	7418,	respectively;	
SEQ	ID	NO:	7425,	and	SEQ	ID	NO:	7418,	respectively;	
SEQ	ID	NO:	7428,	and	SEQ	ID	NO:	7418,	respectively;	
SEQ	ID	NO:	7431,	and	SEQ	ID	NO:	7418,	respectively;	
SEQ	ID	NO:	8059,	and	SEQ	ID	NO:	8060,	respectively;	
SEQ	ID	NO:	8061,	and	SEQ	ID	NO:	8062,	respectively;	
SEQ	ID	NO:	8063,	and	SEQ	ID	NO:	8064,	respectively;	
SEQ	ID	NO:	8065,	and	SEQ	ID	NO:	8066,	respectively;	
SEQ	ID	NO:	8067,	and	SEQ	ID	NO:	8068,	respectively;	
SEQ	ID	NO:	8069,	and	SEQ	ID	NO:	8070,	respectively;	
SEQ	ID	NO:	8071,	and	SEQ	ID	NO:	8072,	respectively;	
SEQ	ID	NO:	8073,	and	SEQ	ID	NO:	8074,	respectively;	
SEQ	ID	NO:	8075,	and	SEQ	ID	NO:	8076,	respectively;	
SEQ	ID	NO:	8077,	and	SEQ	ID	NO:	8078,	respectively;	
SEQ	ID	NO:	8079,	and	SEQ	ID	NO:	8080,	respectively;	
SEQ	ID	NO:	8081,	and	SEQ	ID	NO:	8670,	respectively;	
SEQ	ID	NO:	8082,	and	SEQ	ID	NO:	8083,	respectively;	
SEQ	ID	NO:	8084,	and	SEQ	ID	NO:	8085,	respectively;	
SEQ	ID	NO:	8086	,	and	SEQ	ID	NO:	8087,	respectively;
SEQ	ID	NO:	8088,	and	SEQ	ID	NO:	8089,	respectively;	
SEQ	ID	NO:	8090,	and	SEQ	ID	NO:	8091,	respectively;	
SEQ	ID	NO:	8092,	and	SEQ	ID	NO:	8093,	respectively;	
SEQ	ID	NO:	8094,	and	SEQ	ID	NO:	8095,	respectively;	
SEQ	ID	NO:	8096,	and	SEQ	ID	NO:	8097,	respectively;	
SEQ	ID	NO:	8098,	and	SEQ	ID	NO:	8099,	respectively;	
SEQ	ID	NO:	8100,	and	SEQ	ID	NO:	8101,	respectively;	
SEQ	ID	NO:	8102,	and	SEQ	ID	NO:	8103,	respectively;	
SEQ	ID	NO:	8104,	and	SEQ	ID	NO:	8105,	respectively;	
SEQ	ID	NO:	8106,	and	SEQ	ID	NO:	8107,	respectively;	
SEQ	ID	NO:	8108,	and	SEQ	ID	NO:	8109,	respectively;	
SEQ	ID	NO:	8110,	and	SEQ	ID	NO:	8112,	respectively;	
SEQ	ID	NO:	8113,	and	SEQ	ID	NO:	8114,	respectively;	
SEQ	ID	NO:	8115,	and	SEQ	ID	NO:	8116,	respectively;	
SEQ	ID	NO:	8117,	and	SEQ	ID	NO:	8118,	respectively;	
SEQ	ID	NO:	8119,	and	SEQ	ID	NO:	8120,	respectively;	

SEQ	ID	NO:	8121,	and	SEQ	ID	NO:	8122,	respectively;
SEQ	ID	NO:	8123,	and	SEQ	ID	NO:	8124,	respectively;
SEQ	ID	NO:	8125,	and	SEQ	ID	NO:	8126,	respectively;
SEQ	ID	NO:	8127,	and	SEQ	ID	NO:	8128,	respectively;
SEQ	ID	NO:	8129,	and	SEQ	ID	NO:	8130,	respectively;
SEQ	ID	NO:	8131,	and	SEQ	ID	NO:	8132,	respectively;
SEQ	ID	NO:	8133,	and	SEQ	ID	NO:	8134,	respectively;
SEQ	ID	NO:	8135,	and	SEQ	ID	NO:	8136,	respectively;
SEQ	ID	NO:	8137,	and	SEQ	ID	NO:	8138,	respectively;
SEQ	ID	NO:	8139,	and	SEQ	ID	NO:	8140,	respectively;
SEQ	ID	NO:	8141,	and	SEQ	ID	NO:	8142,	respectively;
SEQ	ID	NO:	8143,	and	SEQ	ID	NO:	8144,	respectively;
SEQ	ID	NO:	8145,	and	SEQ	ID	NO:	8146,	respectively;
SEQ	ID	NO:	8147,	and	SEQ	ID	NO:	8148,	respectively;
SEQ	ID	NO:	8149,	and	SEQ	ID	NO:	8150,	respectively;
SEQ	ID	NO:	8151,	and	SEQ	ID	NO:	8152,	respectively;
SEQ	ID	NO:	8153,	and	SEQ	ID	NO:	8154,	respectively;
SEQ	ID	NO:	8155,	and	SEQ	ID	NO:	8156,	respectively;
SEQ	ID	NO:	8157,	and	SEQ	ID	NO:	8158,	respectively;
SEQ	ID	NO:	8159,	and	SEQ	ID	NO:	8160,	respectively;
SEQ	ID	NO:	8161,	and	SEQ	ID	NO:	8162,	respectively;
SEQ	ID	NO:	8163,	and	SEQ	ID	NO:	8164,	respectively;
SEQ	ID	NO:	8165,	and	SEQ	ID	NO:	8166,	respectively;
SEQ	ID	NO:	8167,	and	SEQ	ID	NO:	8168,	respectively;
SEQ	ID	NO:	8169,	and	SEQ	ID	NO:	8170,	respectively;
SEQ	ID	NO:	8171,	and	SEQ	ID	NO:	8172,	respectively;
SEQ	ID	NO:	8173,	and	SEQ	ID	NO:	8174,	respectively;
SEQ	ID	NO:	8175,	and	SEQ	ID	NO:	8176,	respectively;
SEQ	ID	NO:	8177,	and	SEQ	ID	NO:	8178,	respectively;
SEQ	ID	NO:	8179,	and	SEQ	ID	NO:	8180,	respectively;
SEQ	ID	NO:	8181,	and	SEQ	ID	NO:	8182,	respectively;
SEQ	ID	NO:	8183,	and	SEQ	ID	NO:	8184,	respectively;
SEQ	ID	NO:	8185,	and	SEQ	ID	NO:	8186,	respectively;
SEQ	ID	NO:	8187,	and	SEQ	ID	NO:	8188,	respectively;
SEQ	ID	NO:	8189,	and	SEQ	ID	NO:	8190,	respectively;
SEQ	ID	NO:	8191,	and	SEQ	ID	NO:	8192,	respectively;

SEQ ID NO: 8193, and SEQ ID NO: 8194, respectively;
 SEQ ID NO: 8195, and SEQ ID NO: 8196, respectively;
 SEQ ID NO: 8197, and SEQ ID NO: 8198, respectively;
 SEQ ID NO: 8199, and SEQ ID NO: 8200, respectively;
 SEQ ID NO: 8201, and SEQ ID NO: 8202, respectively;
 SEQ ID NO: 8011, and SEQ ID NO: 8012, respectively;
 SEQ ID NO: 8203, and SEQ ID NO: 8204, respectively; or
 SEQ ID NO: 8205, and SEQ ID NO: 8206, respectively; ~~second antigen-binding domain comprises one or more CDRs, framework regions, variable regions, or antigen binding domains disclosed in any of Table 20A or Table 20B, Table 22, Table 23A or Table 23B, Table 24, Table 25, Table 26, Table 21A or Table 21B,, and Table 17, or a sequence having at least 85%, 90%, 95%, or 99% identity thereto.~~

10. The multifunctional molecule of any one of claims 1 and 15-9, wherein the TRBC is TRBC2, and the first antigen binding domain comprises:

(i) a VH comprising any one sequence selected from the group consisting of SEQ ID NO: 8284, SEQ ID NO: 8295, SEQ ID NO: 7411, SEQ ID NO: 7412, SEQ ID NO: 7413, SEQ ID NO: 7414, SEQ ID NO: 7415, SEQ ID NO: 7416, SEQ ID NO: 7417, SEQ ID NO: 7420, SEQ ID NO: 7423, SEQ ID NO: 7425, SEQ ID NO: 7428, SEQ ID NO: 7431, SEQ ID NO: 8011, SEQ ID NO: 8013, SEQ ID NO: 8020, and SEQ ID NO: 8022; and

(ii) a VL comprising any one sequence selected from the group consisting of SEQ ID NO: 8282, SEQ ID NO: 8293, SEQ ID NO: 7418, SEQ ID NO: 7419, SEQ ID NO: 8012, SEQ ID NO: 8014, SEQ ID NO: 8021, and SEQ ID NO: 8023; ~~second antigen-binding domain comprises a VH comprising a heavy chain complementarity determining region 1 (VHCDR1), a VHCDR2, and a VHCDR3, and a VL comprising a light chain complementarity determining region 1 (VLCDR1), a VLCDR2, and a VLCDR3, wherein the VHCDR1, VHCDR2, and VHCDR3 of the second antigen binding domain comprise the amino acid sequences of:~~

~~SEQ ID NOs: 7313, 6001, and 7315, respectively;~~

~~SEQ ID NOs: 7313, 6001, and 6002, respectively;~~

~~SEQ ID NOs: 7313, 6008, and 6009, respectively;~~

~~SEQ ID NOs: 7313, 7385, and 7315, respectively;~~

~~SEQ ID NOs: 7313, 7318, and 6009, respectively;~~

~~SEQ ID NOs: C019, C021, and C023, respectively;~~

~~SEQ ID NOs: C033, C035, and C037, respectively;~~

~~SEQ ID NOs: C047, C049, and C051, respectively;~~

~~SEQ ID NOs: C061, C063, and C065, respectively;~~

~~SEQ ID NOs: C075, C077, and C079, respectively;~~

~~SEQ ID NOs: C089, C091, and C093, respectively;~~

~~SEQ ID NOs: C103, C105, and C107, respectively; or~~

~~SEQ ID NOs: C116, C118, and C120, respectively.~~

11. The multifunctional molecule of any one of claims 1-10, wherein the TRBC is TRBC2, and the first antigen binding domain comprises a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 7433, SEQ ID NO: 7434, SEQ ID NO: 7435, SEQ ID NO: 7436, and SEQ ID NO: 7437VLCDR1, VLCDR2, and VLCDR3 of the second antigen binding domain ~~comprise the amino acid sequences of:~~

~~SEQ ID NOs: 7326, 7327, and 7329, respectively;~~

~~SEQ ID NOs: 6063, 6064, and 7293, respectively;~~

~~SEQ ID NOs: 6070, 6071, and 6072, respectively;~~

~~SEQ ID NOs: 6070, 6064, and 7321, respectively;~~

~~SEQ ID NOs: C026, C028, and C030, respectively;~~

~~SEQ ID NOs: C040, C042, and C044, respectively;~~

~~SEQ ID NOs: C054, C056, and C058, respectively;~~

~~SEQ ID NOs: C068, C070, and C072, respectively;~~

~~SEQ ID NOs: C082, C084, and C086, respectively;~~

~~SEQ ID NOs: C096, C098, and C100, respectively;~~

~~SEQ ID NOs: C110, C112, and C113, respectively; or~~

~~SEQ ID NOs: C123, C125, and C127, respectively.~~

12. The multifunctional molecule of any one of claims 1-10 or 11, wherein the TRBC is TRBC2, and the first antigen binding domain comprises any one sequence selected from the group consisting of SEQ ID NO: 7433, SEQ ID NO: 7434, SEQ ID NO: 7435, SEQ ID NO: 7436, and SEQ ID NO: 7437VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 of the second antigen binding domain ~~comprise the amino acid sequences of:~~

~~SEQ ID NOs: 7313, 6001, 7315, 7326, 7327, and 7329, respectively;~~

~~SEQ ID NOs: 7313, 6001, 6002, 6063, 6064, and 7293, respectively;~~

~~SEQ ID NOs: 7313, 6008, 6009, 6070, 6071, and 6072, respectively;~~

~~SEQ ID NOs: 7313, 7385, 7315, 6070, 6064, and 7321, respectively;~~

~~SEQ ID NOs: 7313, 7318, 6009, 6070, 6064, and 7321, respectively;~~

~~SEQ ID NOs: C019, C021, C023, C026, C028, and C030, respectively;~~

~~SEQ ID NOs: C033, C035, C037, C040, C042, and C044, respectively;~~

~~SEQ ID NOs: C047, C049, C051, C054, C056, and C058, respectively;~~

~~SEQ ID NOs: C061, C063, C065, C068, C070, and C072, respectively;~~

~~SEQ ID NOs: C075, C077, C079, C082, C084, and C086, respectively;~~

~~SEQ ID NOs: C089, C091, C093, C096, C098, and C100, respectively;~~

~~SEQ ID NOs: C103, C105, C107, C110, C112, and C113, respectively; or~~

~~SEQ ID NOs: C116, C118, C120, C123, C125, and C127, respectively.~~

13. The multifunctional molecule of any one of claims 140-12, wherein the second antigen binding domain that binds to NKp30 comprises:

(A) (i) a VH comprising a VHCDR1, a VHCDR2, and a VHCDR3 that comprise the sequences of:
SEQ ID NO: 8053, SEQ ID NO: 8289, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8288, SEQ ID NO: 8289, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8053, SEQ ID NO: 8688, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 6001, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 6001, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 6000, SEQ ID NO: 6008, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 6008, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 6000, SEQ ID NO: 7385, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 7318, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 7318, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8636, SEQ ID NO: 8688, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6001, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6008, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7385, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7318, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8636, SEQ ID NO: 6001, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8636, SEQ ID NO: 8688, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6001, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6008, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7385, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7318, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8636, SEQ ID NO: 6001, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8636, SEQ ID NO: 8688, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6001, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6008, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7385, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7318, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8636, SEQ ID NO: 6001, and SEQ ID NO: 8290, respectively; or
SEQ ID NO: 8636, SEQ ID NO: 8688, and SEQ ID NO: 8290; and/or
(ii) a VL comprising a VLCDR1, a VLCDR2, and a VLCDR3 that comprise the sequences of:
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 7329, respectively;

SEQ ID NO: 6070, SEQ ID NO: 6064, and SEQ ID NO: 7321, respectively;
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 8689, respectively;
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 8690, respectively;
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 7329, respectively;
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 8691, respectively;
SEQ ID NO: 6063, SEQ ID NO: 6064, and SEQ ID NO: 7293, respectively; or
SEQ ID NO: 6070, SEQ ID NO: 6071, and SEQ ID NO: 6072, respectively; or
 (B) a VH and a VL respectively comprising a VHCDR1, a VHCDR2, and a VHCDR3; and a
 VLCDR1, a VLCDR2, and a VLCDR3 that comprise the sequences of:
SEQ ID NOs: 7313, 6001, 7315, 7326, 7327, and 7329, respectively;
SEQ ID NOs: 7313, 6001, 6002, 6063, 6064, and 7293, respectively;
SEQ ID NOs: 7313, 6008, 6009, 6070, 6071, and 6072, respectively;
SEQ ID NOs: 7313, 7385, 7315, 6070, 6064, and 7321, respectively;
SEQ ID NOs: 7313, 7318, 6009, 6070, 6064, and 7321, respectively;
SEQ ID NOs: 8053, 6001, 7315, 7326, 7327, and 8689, respectively;
SEQ ID NOs: 8053, 6001, 7315, 7326, 7327, and 8690, respectively;
SEQ ID NOs: 8053, 6001, 7315, 7326, 7327, and 8690, respectively;
SEQ ID NOs: 8053, 6001, 7315, 7326, 7327, and 8689, respectively;
SEQ ID NOs: 8053, 8688, 7315, 7326, 7327, and 7329, respectively;
SEQ ID NOs: 8053, 8688, 7315, 7326, 7327, and 7329, respectively;
SEQ ID NOs: 8053, 8688, 7315, 7326, 7327, and 8691, respectively; or
SEQ ID NOs: 8053, 8688, 7315, 7326, 7327, and 8691, respectively

(i) the VH of the second antigen-binding domain comprises an amino acid sequence selected from the group consisting of **SEQ ID NOs: 7302, 7298, 7300, 7301, 7303, and 7304** (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto) and/or the VL of the second antigen-binding domain comprises an amino acid sequence selected from the group consisting of **SEQ ID NOs: 7309, 7305, 7299, and 7306-7308** (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);

(ii) the VH of the second antigen-binding domain comprises an amino acid sequence selected from the group consisting of **SEQ ID NOs: 6121 or 6123-6128** (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto) and/or the VL of the second antigen-binding domain comprises an amino acid sequence selected from the group consisting of **SEQ ID NOs: 7294 or 6137-6141** (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto); or

(iii) the VH of the second antigen-binding domain comprises an amino acid sequence selected from the group consisting of **SEQ ID NOs: 6122 or 6129-6134** (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto) and/or the VL of the second antigen-binding domain comprises an

~~amino acid sequence selected from the group consisting of SEQ ID NOs: 6136 or 6142-6147 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto) or~~

~~(iv) the VH of the second antigen binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: C001-C008 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto) and/or the VL of the second antigen binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: C009-C016 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto).~~

14. The multifunctional molecule of any one of claims ~~14~~10-13, wherein the second antigen binding domain that binds to NKp30 comprises~~VH and VL of the second antigen binding domain comprise the amino acid sequences of:~~

(i) a VH comprising a VHCDR1, a VHCDR2, and a VHCDR3 that comprise the sequences of:
SEQ ID NO: 8053, SEQ ID NO: 8289, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8288, SEQ ID NO: 8289, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8053, SEQ ID NO: 8688, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 6001, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 6001, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 6000, SEQ ID NO: 6008, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 6008, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 6000, SEQ ID NO: 7385, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 7318, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 6000, SEQ ID NO: 7318, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8636, SEQ ID NO: 8688, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6001, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6008, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7385, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7318, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8636, SEQ ID NO: 6001, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8636, SEQ ID NO: 8688, and SEQ ID NO: 6002, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6001, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6008, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7385, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7318, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8636, SEQ ID NO: 6001, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8636, SEQ ID NO: 8688, and SEQ ID NO: 6009, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6001, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8554, SEQ ID NO: 6008, and SEQ ID NO: 8290, respectively;

SEQ ID NO: 8554, SEQ ID NO: 7385, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8554, SEQ ID NO: 7318, and SEQ ID NO: 8290, respectively;
SEQ ID NO: 8636, SEQ ID NO: 6001, and SEQ ID NO: 8290, respectively; or
SEQ ID NO: 8636, SEQ ID NO: 8688, and SEQ ID NO: 8290; and
(ii) a VL comprising a VLCDR1, a VLCDR2, and a VLCDR3 that comprise the sequences of:
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 7329, respectively;
SEQ ID NO: 6070, SEQ ID NO: 6064, and SEQ ID NO: 7321, respectively;
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 8689, respectively;
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 8690, respectively;
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 7329, respectively;
SEQ ID NO: 7326, SEQ ID NO: 7327, and SEQ ID NO: 8691, respectively;
SEQ ID NO: 6063, SEQ ID NO: 6064, and SEQ ID NO: 7293, respectively; or
SEQ ID NO: 6070, SEQ ID NO: 6071, and SEQ ID NO: 6072, respectively
~~SEQ ID NOs: 7302 and 7309, respectively (or a sequence having at least 85%, 90%, 95%, or 99%~~
~~identity thereto);~~
~~SEQ ID NOs: 7302 and 7305, respectively (or a sequence having at least 85%, 90%, 95%, or 99%~~
~~identity thereto) or~~
any of ~~SEQ ID NOs: C017-C024.~~

15. The multifunctional molecule of any one of claims ~~14~~11-14, wherein the second antigen binding domain that binds to NKp30 comprises~~comprise the amino acid sequences of:~~
(ii) a VH comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 8030, SEQ ID NOs: 6121-6134, SEQ ID NO: 7295, SEQ ID NO: 7297, SEQ ID NO: 7298, SEQ ID NOs: 7300-7304, and SEQ ID NO: 8692, optionally, wherein the VH comprises any one sequence selected from the group consisting of SEQ ID NO: 8030, SEQ ID NOs: 6121-6134, SEQ ID NO: 7295, SEQ ID NO: 7297, SEQ ID NO: 7298, SEQ ID NOs: 7300-7304, and SEQ ID NO: 8692; and/or
(ii) a VL comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 7309, SEQ ID NO: 7294, SEQ ID NOs: 6136-6147, SEQ ID NO: 7296, SEQ ID NO: 7299, SEQ ID NOs: 7305-7309, and SEQ ID NOs: 8693-8698, optionally, wherein the VL comprises any one sequence selected from the group consisting of SEQ ID NO: 7309, SEQ ID NO: 7294, SEQ ID NOs: 6136-6147, SEQ ID NO: 7296, SEQ ID NO: 7299, SEQ ID NOs: 7305-7309, and SEQ ID NOs: 8693-8698
~~SEQ ID NO: 7311 or 7310 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~
~~SEQ ID NO: 6187 or 6188 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~
or
~~SEQ ID NO: 6189 or 6190 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto).~~

16. The multifunctional molecule of any one of claims 1-15, wherein the second antigen binding domain that binds to NKp30 comprises:
- (i) a VH comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 8030, SEQ ID NOs: 6121-6134, SEQ ID NO: 7295, SEQ ID NO: 7297, SEQ ID NO: 7298, SEQ ID NOs: 7300-7304, and SEQ ID NO: 8692, optionally, wherein the VH comprises any one sequence selected from the group consisting of SEQ ID NO: 8030, SEQ ID NOs: 6121-6134, SEQ ID NO: 7295, SEQ ID NO: 7297, SEQ ID NO: 7298, SEQ ID NOs: 7300-7304, and SEQ ID NO: 8692; and
- (ii) a VL comprising a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 7309, SEQ ID NO: 7294, SEQ ID NOs: 6136-6147, SEQ ID NO: 7296, SEQ ID NO: 7299, SEQ ID NOs: 7305-7309, and SEQ ID NOs: 8693-8698, optionally, wherein the VL comprises any one sequence selected from the group consisting of SEQ ID NO: 7309, SEQ ID NO: 7294, SEQ ID NOs: 6136-6147, SEQ ID NO: 7296, SEQ ID NO: 7299, SEQ ID NOs: 7305-7309, and SEQ ID NOs: 8693-8698 ~~multifunctional molecule binds to TRBC2 monovalently.~~
17. The multifunctional molecule of any one of claims 1-16, wherein the second antigen binding domain that binds to NKp30 comprises a VH and a VL comprising the sequences of~~multifunctional molecule comprises a configuration shown in any of FIGs. 30A-30D,~~ wherein:
- | | | | | | |
|------------|------|-----|------------|-------|---------------|
| SEQ ID NO: | 8030 | and | SEQ ID NO: | 7309, | respectively; |
| SEQ ID NO: | 6121 | and | SEQ ID NO: | 7294, | respectively; |
| SEQ ID NO: | 6122 | and | SEQ ID NO: | 6136, | respectively; |
| SEQ ID NO: | 6123 | and | SEQ ID NO: | 6137, | respectively; |
| SEQ ID NO: | 6124 | and | SEQ ID NO: | 6138, | respectively; |
| SEQ ID NO: | 6125 | and | SEQ ID NO: | 6139, | respectively; |
| SEQ ID NO: | 6126 | and | SEQ ID NO: | 6140, | respectively; |
| SEQ ID NO: | 6127 | and | SEQ ID NO: | 6141, | respectively; |
| SEQ ID NO: | 6129 | and | SEQ ID NO: | 6142, | respectively; |
| SEQ ID NO: | 6130 | and | SEQ ID NO: | 6143, | respectively; |
| SEQ ID NO: | 6131 | and | SEQ ID NO: | 6144, | respectively; |
| SEQ ID NO: | 6132 | and | SEQ ID NO: | 6145, | respectively; |
| SEQ ID NO: | 6133 | and | SEQ ID NO: | 6146, | respectively; |
| SEQ ID NO: | 6134 | and | SEQ ID NO: | 6147, | respectively; |
| SEQ ID NO: | 7295 | and | SEQ ID NO: | 7296, | respectively; |
| SEQ ID NO: | 7297 | and | SEQ ID NO: | 7296, | respectively; |
| SEQ ID NO: | 6122 | and | SEQ ID NO: | 6136, | respectively; |
| SEQ ID NO: | 7298 | and | SEQ ID NO: | 7299, | respectively; |

~~SEQ ID NO: 7300 and SEQ ID NO: 7305, respectively;~~
~~SEQ ID NO: 7301 and SEQ ID NO: 7306, respectively;~~
~~SEQ ID NO: 7302 and SEQ ID NO: 7307, respectively;~~
~~SEQ ID NO: 7303 and SEQ ID NO: 7308, respectively;~~
~~SEQ ID NO: 7304 and SEQ ID NO: 7309, respectively;~~
~~SEQ ID NO: 7302 and SEQ ID NO: 7305, respectively;~~
~~SEQ ID NO: 7302 and SEQ ID NO: 7309, respectively;~~
~~SEQ ID NO: 7302 and SEQ ID NO: 8693, respectively;~~
~~SEQ ID NO: 7302 and SEQ ID NO: 8694, respectively;~~
~~SEQ ID NO: 7302 and SEQ ID NO: 8695, respectively;~~
~~SEQ ID NO: 7302 and SEQ ID NO: 8696, respectively;~~
~~SEQ ID NO: 8692 and SEQ ID NO: 7309, respectively;~~
~~SEQ ID NO: 8692 and SEQ ID NO: 7305, respectively;~~
~~SEQ ID NO: 8692 and SEQ ID NO: 8697, respectively; or~~
~~SEQ ID NO: 8692 and SEQ ID NO: 8698, respectively~~

- ~~(i) the multifunctional antibody molecule comprises an anti-TRBC2 Fab and an anti-NKp30 scFv, e.g., comprises a configuration shown in FIG. 30A;~~
 - ~~(ii) the multifunctional antibody molecule comprises an anti-TRBC2 Fab and an anti-NKp30 Fab, e.g., comprises a configuration shown in FIG. 30B;~~
 - ~~(iii) the multifunctional antibody molecule comprises an anti-NKp30 Fab and an anti-TRBC2 scFv, e.g., comprises a configuration shown in FIG. 30C; or~~
 - ~~(iv) the multifunctional antibody molecule comprises an anti-TRBC2 scFv and an anti-NKp30 scFv, e.g., comprises a configuration shown in FIG. 30D.~~
18. The multifunctional molecule of any one of claims 1-17, wherein the second antigen binding domain that binds to NKp30 comprises a sequence having at least 85% identity to any one sequence selected from the group consisting of SEQ ID NO: 8287, SEQ ID NO: 6187, SEQ ID NO: 6188, SEQ ID NO: 6189, SEQ ID NO: 6190, SEQ ID NO: 7310, SEQ ID NO: 7311, SEQ ID NO: 8699, SEQ ID NO: 8700, SEQ ID NO: 8701, SEQ ID NO: 8702, SEQ ID NO: 8703, SEQ ID NO: 8704, SEQ ID NO: 8705, and SEQ ID NO: 8706~~further comprising a dimerization module comprising one or more immunoglobulin chain constant regions (e.g., Fc regions) comprising one or more of: a paired cavity-protuberance (“knob-in-a-hole”), an electrostatic interaction, or a strand-exchange.~~
19. The multifunctional molecule of any one of claims 1-18, wherein the second antigen binding domain that binds to NKp30 comprises any one sequence selected from the group consisting of SEQ ID NO: 8287, SEQ ID NO: 6187, SEQ ID NO: 6188, SEQ ID NO: 6189, SEQ ID NO: 6190, SEQ ID NO: 7310, SEQ ID NO: 7311, SEQ ID NO: 8699, SEQ ID NO: 8700, SEQ ID NO: 8701, SEQ ID NO: 8702, SEQ ID NO: 8703, SEQ ID NO: 8704, SEQ ID NO: 8705, and SEQ ID NO: 8706~~comprising~~

~~an anti-TRBC2 amino acid sequence disclosed in any of Table 9A or Table 9B, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15, Table 17, Table 39 or a sequence having at least 85%, 90%, 95%, or 99% identity thereto, and/or an anti-NKp30 amino acid sequence disclosed in any of Tables, Table 20A or Table 20B, Table 22, Table 23A or Table 23B, Table 24, Table 25, Table 26, Table 21A or Table 21B,, Table 17, and Table 15 or a sequence having at least 85%, 90%, 95%, or 99% identity thereto.~~

20. The multifunctional molecule of any one of claims 1-19, wherein the second antigen binding domain that binds to NKp30 comprises~~comprising~~:
- (i) a sequence having at least 85% identity to SEQ ID NO: 6148 or SEQ ID NO: 6149, and a sequence having at least 85% identity to SEQ ID NO: 6150; or~~an anti-TRBC2 VH of SEQ ID NO: 7420 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), an anti-TRBC2 VL of SEQ ID NO: 7419 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), an anti-NKp30 VH of SEQ ID NO: 7302 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), and an anti-NKp30 VL of SEQ ID NO: 7309 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~
 - (ii) a sequence having at least 85% identity to SEQ ID NO: 6151 or SEQ ID NO: 6152, and a sequence having at least 85% identity to SEQ ID NO: 6153~~an anti-TRBC2 VH of SEQ ID NO: 7420 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), an anti-TRBC2 VL of SEQ ID NO: 7419 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), and an anti-NKp30 scFv of SEQ ID NO: 7311 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto); or~~
 - (iii) ~~SEQ ID NOs: 7438, 7439, and 7383 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto).~~
21. The multifunctional molecule of any one of claims 1-20~~19~~, wherein the second antigen binding domain that binds to NKp30 comprises~~comprising~~:
- (i) the sequence of SEQ ID NO: 6148 or the sequence of SEQ ID NO: 6149, and the sequence of SEQ ID NO: 6150; or~~an anti-TRBC2 VH of SEQ ID NO: 7423 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), an anti-TRBC2 VL of SEQ ID NO: 7419 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), an anti-NKp30 VH of SEQ ID NO: 7302 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), and an anti-NKp30 VL of SEQ ID NO: 7309 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto);~~
 - (ii) the sequence of SEQ ID NO: 6151 or the sequence of SEQ ID NO: 6152, and the sequence of SEQ ID NO: 6153~~an anti-TRBC2 VH of SEQ ID NO: 7423 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), an anti-TRBC2 VL of SEQ ID NO: 7419 (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto), and an anti-NKp30 scFv of SEQ ID NO: 7311~~

- (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto); or (iii) **SEQ ID NOs: 7440, 7439, and 7383** (or a sequence having at least 85%, 90%, 95%, or 99% identity thereto).
22. A multifunctional molecule of any one of claims 1-21, wherein the multifunctional molecule comprises a dimerization module comprising one or more immunoglobulin chain constant regions, and optionally, wherein the one or more immunoglobulin chain constant regions are Fc regions comprising one or more of: a paired cavity-protuberance, an electrostatic interaction, or a strand-exchangecomprising: (i) a first antigen-binding domain that binds to T-cell receptor beta chain constant domain 1 (TRBC1), and (ii) a second antigen-binding domain that binds to NKp30, wherein the first antigen-binding domain comprises one or more CDRs, framework regions, variable regions, or antigen-binding domains disclosed in any of Table 5A or Table 5B, Table 5A or Table 5B, Table 6, or Table 7 (e.g., any of **SEQ ID NOs: B001-B095**), or a sequence having at least 85%, 90%, 95%, or 99% identity thereto.
 23. The multifunctional molecule of any one of claims 1-22, wherein the multifunctional molecule comprises:
 - (i) a heavy chain constant region variant comprising one or more mutations that result in reduced or ablated affinity for at least one Fc receptor; and/or
 - (ii) a kappa light chain polypeptide, and a lambda light chain polypeptidesecond antigen-binding domain comprises one or more CDRs, framework regions, variable regions, or antigen-binding domains disclosed herein.
 24. A multifunctional molecule of any one of claims 1-23, wherein the multifunctional molecule further comprises one, two, or all of a cytokine molecule, a cytokine inhibitor molecule, a death receptor signal engager, and a stromal modifying moiety comprising:
 - (i) a first antigen-binding domain that binds to T-cell receptor beta chain constant domain 1 (TRBC1), and
 - (ii) a second antigen-binding domain that binds to NKp30,
 wherein the second antigen-binding domain comprises one or more CDRs, framework regions, variable regions, or antigen-binding domains disclosed in any of Tables, Table 23A or Table 23B, Table 24, Table 25, or Table 26 (e.g., any of **SEQ ID NOs C001-C128**); or a sequence having at least 85%, 90%, 95%, or 99% identity thereto.
 25. The multifunctional molecule of claim 24, wherein:
 - (i) the cytokine molecule is selected from the group consisting of interleukin-2 (IL-2) or functional variant thereof, interleukin-7 (IL-7) or functional variant thereof, interleukin-12 (IL-12) or functional variant thereof, interleukin-15 (IL-15) or functional variant thereof, interleukin-18 (IL-18) or functional variant thereof, interleukin-21 (IL-21) or functional variant thereof, interferon gamma or functional variant thereof, and any combination thereof;
 - (ii) the cytokine inhibitor molecule is a TGF-beta inhibitor; and/or

- (iii) the death receptor signal engager is selected from the group consisting of a TNF-related apoptosis-inducing ligand (TRAIL) molecule, a death receptor molecule, and an antigen binding domain that specifically binds to a death receptor ~~the first antigen binding domain comprises one or more CDRs, framework regions, variable regions, or antigen binding domains disclosed herein.~~
26. ~~An antibody molecule that binds to TRBC2, comprising one or more CDRs, framework regions, variable regions, or antigen binding domains disclosed in any of Table 9A or Table 9B, Table 10, Table 11, Table 12, Table 13, Table 14, Table 15, and Table 17, Table 39, or a sequence having at least 85%, 90%, 95%, or 99% identity thereto.~~
27. ~~An antibody molecule that binds to TRBC1, comprising one or more CDRs, framework regions, variable regions, or antigen binding domains disclosed in any of Table 5A or Table 5B, Table 5A or Table 5B, Table 6, or Table 7 (e.g., any of **SEQ ID NOs:** B001-B095), or a sequence having at least 85%, 90%, 95%, or 99% identity thereto.~~
28. ~~The multifunctional molecule of any of claims 1-21 or the antibody molecule of claim 22, further comprising a heavy chain constant region variant, e.g., an Fc region variant, that comprises one or more mutations that result in reduced or ablated affinity for at least one Fc receptor, optionally wherein the one or more mutations result in reduced or ablated antibody dependent cell mediated cytotoxicity (ADCC), Antibody dependent cellular phagocytosis (ADCP), or complement dependent cytotoxicity (CDC).~~
29. ~~The multifunctional molecule of any of claims 1-25, or the antibody molecule of claim 26 or 27, wherein the Fc region variant comprises one or more mutations disclosed in Table 18, optionally wherein the Fc region variant comprises an N297A mutation.~~
30. ~~A nucleic acid molecule encoding the multifunctional molecule of any of claims 1-25, or the antibody molecule of claim 26 or 27.~~
31. ~~A vector comprising the nucleic acid molecule of claim 30.~~
32. ~~A cell comprising the nucleic acid molecule of claim 30 or the vector of claim 31.~~
33. ~~A method of making, e.g., producing, the multifunctional molecule of any of claims 1-25, or the antibody molecule of any of claims 26-27, comprising culturing the cell of claim 32, under conditions suitable for gene expression and/or homo- or heterodimerization.~~
34. ~~A pharmaceutical composition comprising the multifunctional molecule of any of claims 1-25, or the antibody molecule of any of claims 26-27 and a pharmaceutically acceptable carrier, excipient, or stabilizer.~~
35. ~~A method of treating a cancer, comprising administering to a subject in need thereof the multifunctional molecule of any of claims 1-25, wherein the multifunctional molecule is administered in an amount effective to treat the cancer.~~

36. ~~The method of claim 35, further comprising identifying, evaluating, or selecting a subject in need of treatment, wherein identifying, evaluating, or selecting comprises determining whether a subject has cancer cells that express a T cell receptor comprising TRBC2.~~
37. ~~The method of claim 36, further comprising, responsive to determining that a subject has cancer cells that express a T cell receptor comprising TRBC2: selecting the subject for treatment with a multifunctional molecule comprising an antigen binding domain that binds to a T cell receptor comprising TRBC2, and administering a multifunctional molecule comprising an antigen binding domain that binds to a T cell receptor comprising TRBC2.~~
38. ~~A method of treating a cancer comprising, administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 34, or a composition comprising an effective amount of the multifunctional molecule of any one of claims 1-25, 26, or 27.~~
39. ~~The method of claim 38, wherein the cancer is a T cell lymphoma or leukemia wherein the cancer cells express a T cell receptor comprising TRBC2.~~
40. ~~A method of identifying a subject in need for a treatment for cancer, comprising determining the presence or absence of cancer cells that express a T cell receptor comprising TRBC2 in the subject, wherein: determination that the subject has cancer cells that express a T cell receptor comprising TRBC2.~~
41. ~~The method of any of claims 35-40, wherein the cancer is leukemia or lymphoma.~~
42. ~~The method of any of claims 35-41, wherein the cancer is selected from Acquired immune deficiency syndrome (AIDS)-associated lymphoma, Angioimmunoblastic T-cell lymphoma, Adult T-cell leukemia/lymphoma, Burkitt lymphoma, Central nervous system (CNS) lymphoma, Diffuse large B-cell lymphoma (DLBCL), Lymphoblastic lymphoma, Mantle cell lymphoma (MCL), Peripheral T-cell lymphoma (PTCL) (e.g., Hepatosplenic T-cell lymphoma (HSGDTCL), Subcutaneous panniculitis-like T-cell lymphoma, or Enteropathy-associated T-cell lymphoma), Transformed follicular and transformed mucosa-associated lymphoid tissue (MALT) lymphomas, Cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome), Follicular lymphoma, Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, Marginal zone B-cell lymphoma, Gastric mucosa-associated lymphoid tissue (MALT) lymphoma, Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL), Extranodal T-/NK-cell lymphoma (nasal type), and Anaplastic large-cell lymphoma (e.g., primary cutaneous anaplastic large-cell lymphoma or systemic anaplastic large-cell lymphoma).~~
43. ~~The method of any of claims 35-42, wherein the cancer is Peripheral T-cell lymphoma (PTCL).~~
44. ~~A multifunctional molecule, comprising: (i) a first antigen binding domain that binds to T cell receptor beta chain constant domain 2 (TRBC2), comprising a heavy chain comprising heavy chain complementarity determining regions (CDRs) HC-CDR1, HC-CDR2, and HC-CDR3 and a light chain, comprising a light chain comprising light chain complementarity determining regions~~

- (CDRs) LC-CDR1, LC-CDR2, and LC-CDR3 and (ii) a second antigen-binding domain that binds to NKp30.
45. ~~The multifunctional molecule of claim 44, wherein the HC-CDR3 comprises an amino acid sequence of **SEQ ID NO: 8043**.~~
46. ~~The multifunctional molecule of claim 44, wherein the HC-CDR3 comprises an amino acid sequence of **SEQ ID NO: 8045**.~~
47. ~~The multifunctional molecule of claim 44, wherein the HC-CDR3 comprises an amino acid sequence of **SEQ ID NO: 8046**.~~
48. ~~The multifunctional molecule of claim 44, wherein the HC-CDR3 comprises an amino acid sequence of **SEQ ID NO: 8047**.~~
49. ~~The multifunctional molecule of claim 45, wherein the HC-CDR1 comprises an amino acid sequence of **SEQ ID NO: 8041**.~~
50. ~~The multifunctional molecule of claim 45 or 49, wherein the HC-CDR2 comprises an amino acid sequence of **SEQ ID NO: 8** or **SEQ ID NO: 8044**.~~
51. ~~The multifunctional molecule of any one of the claims 45, 49 or 50, wherein the LC-CDR1 comprises an amino acid sequence of **SEQ ID NO: 8045** or **SEQ ID NO: 8051**.~~
52. ~~The multifunctional molecule of any one of the claims 45, 49-51, wherein the LC-CDR2 comprises an amino acid sequence of **SEQ ID NO: 8049**.~~
53. ~~The multifunctional molecule of any one of the claims 45, 49-52, wherein the LC-CDR3 comprises an amino acid sequence of **SEQ ID NO: 8050** or **8052**.~~
54. ~~The multifunctional molecule of any one of the claims 45, 49-53, wherein the second antigen binding domain that binds to NKp30 comprises a heavy chain comprising heavy chain complementarity determining regions (CDRs) HC-CDR1, HC-CDR2, and HC-CDR3 and a light chain, comprising a light chain comprising light chain complementarity determining regions (CDRs) LC-CDR1, LC-CDR2, and LC-CDR3, wherein the heavy chain comprises a HC-CDR3 amino acid sequence of **SEQ ID NO: 8055**.~~
55. ~~The multifunctional molecule of any one of the claims 45, 49-54, wherein the second antigen binding domain comprises a light chain complementarity determining region LC-CDR3 amino acid sequence of **SEQ ID NO: 8058**.~~
56. ~~The multifunctional molecule of any one of the claims 45, 49-55, wherein the NKp30 binding domain comprises a heavy chain comprising a HC-CDR1 amino acid sequence of **SEQ ID NO: 8053**; and a HC-CDR2 amino acid sequence of **SEQ ID NO: 8054**.~~
57. ~~The multifunctional molecule of any one of the claims 45, 49-56, wherein the NKp30 binding domain comprises a light chain comprising a LC-CDR1 amino acid sequence of **SEQ ID NO: 8056** and a LC-CDR2 amino acid sequence of **SEQ ID NO: 8057**.~~

58. ~~The multifunctional molecule of any one of the claims 45, 49-57, wherein the TRBC2 binding domain comprises a heavy chain that is at least 90% identical to **SEQ ID NO: 8011**.~~
59. ~~The multifunctional molecule of any one of the claims 45, 49-57, wherein the TRBC2 binding domain comprises a light chain that is at least 95% identical to **SEQ ID NO: 8012**.~~
60. ~~The multifunctional molecule of any one of the claims 45, 49-57, wherein the TRBC2 binding domain comprises an scFv.~~
61. ~~The multifunctional molecule of claim 46, wherein the HC CDR1 is **SEQ ID NO: 8041**.~~
62. ~~The multifunctional molecule of claim 46, wherein the HC CDR2 is **SEQ ID NO: 8042** or **SEQ ID NO: 8044**.~~
63. ~~The multifunctional molecule of any one of the claims 46, or 61-62, wherein the LC CDR1 comprises an amino acid sequence of **SEQ ID NO: 8048** or **SEQ ID NO: 8051**.~~
64. ~~The multifunctional molecule of any one of the claims 46, or 61-63, wherein the LC CDR2 comprises an amino acid sequence of **SEQ ID NO: 8049**.~~
65. ~~The multifunctional molecule of any one of the claims 46, or 61-64, wherein the LC CDR3 comprises an amino acid sequence of **SEQ ID NO: 8050** or **8051**.~~
66. ~~The multifunctional molecule of any one of the claims 46, or 61-65, wherein the second antigen binding domain that binds to NKp30 comprises a heavy chain comprising heavy chain complementarity determining regions (CDRs) HC CDR1, HC CDR2, and HC CDR3 and a light chain, comprising a light chain comprising light chain complementarity determining regions (CDRs) LC CDR1, LC CDR2, and LC CDR3, wherein the heavy chain comprises a HC CDR3 amino acid sequence of **SEQ ID NO: 8055**.~~
67. ~~The multifunctional molecule of any one of the claims 46, or 61-66, wherein the second antigen binding domain comprises a light chain complementarity determining region LC CDR3 amino acid sequence of **SEQ ID NO: 8058**.~~
68. ~~The multifunctional molecule of any one of the claims 46, or 61-67, wherein the NKp30 binding domain comprises a heavy chain comprising a HC CDR1 amino acid sequence of **SEQ ID NO: 8053**; and a HC CDR2 amino acid sequence of **SEQ ID NO: 8054**.~~
69. ~~The multifunctional molecule of any one of the claims 46, or 61-68, wherein the NKp30 binding domain comprises a light chain comprising a LC CDR1 amino acid sequence of **SEQ ID NO: 8056** and a LC CDR2 amino acid sequence of **SEQ ID NO: 8057**.~~
70. ~~The multifunctional molecule of any one of the claims 46, or 61-69, wherein the TRBC2 binding domain comprises a heavy chain that is at least 90% identical to **SEQ ID NO: 8011**.~~
71. ~~The multifunctional molecule of any one of the claims 46, or 61-70, wherein the TRBC2 binding domain comprises a light chain that is at least 95% identical to **SEQ ID NO: 8012**.~~
72. ~~The multifunctional molecule of any one of the claims 46, or 61-71, wherein the TRBC2 binding domain comprises an scFv.~~

73. ~~The multifunctional molecule of claim 47 or 48, wherein the HC CDR1 comprises an amino acid sequence of **SEQ ID NO: 8041**.~~
74. ~~The multifunctional molecule of claim 47 or 48, wherein the HC CDR2 is **SEQ ID NO: 8044**.~~
75. ~~The multifunctional molecule of claim 47 or 48, wherein the LC CDR1 comprises an amino acid sequence of **SEQ ID NO: 8048** or **SEQ ID NO: 8051**, the LC CDR2 comprises an amino acid sequence of **SEQ ID NO: 8049**, and the LC CDR3 comprises an amino acid sequence of **SEQ ID NO: 8050** or **8052**.~~
76. ~~The multifunctional molecule of any one of the claims 45-48, wherein the first antigen binding domain comprises an HC CDR1 that comprises an amino acid sequence of **SEQ ID NO: 8041**.~~
77. ~~The multifunctional molecule of any one of the claims 45-48, wherein the first antigen binding domain comprises an HC CDR2 that comprises an amino acid sequence of **SEQ ID NO: 8042**.~~
78. ~~The multifunctional molecule of any one of the claims 45-48, wherein the first antigen binding domain comprises an HC CDR2 that comprises an amino acid sequence of **SEQ ID NO: 8044**.~~
79. ~~The multifunctional molecule of any one of the claims 45-48, wherein the first antigen binding domain comprises an LC CDR1 that comprises an amino acid sequence of **SEQ ID NO: 8048**.~~
80. ~~The multifunctional molecule of any one of the claims 45-48, wherein the first antigen binding domain comprises an LC CDR1 that comprises an amino acid sequence of **SEQ ID NO: 8051**.~~
81. ~~The multifunctional molecule of any one of the claims 45-48, wherein the first antigen binding domain comprises an LC CDR2 that comprises an amino acid sequence of **SEQ ID NO: 8049**.~~
82. ~~The multifunctional molecule of any one of the claims 45-48, wherein the first antigen binding domain comprises an LC CDR3 that comprises an amino acid sequence of **SEQ ID NO: 8050**.~~
83. ~~The multifunctional molecule of any one of the claims 45-48, wherein the first antigen binding domain comprises an LC CDR3 that comprises an amino acid sequence of **SEQ ID NO: 8052**.~~
84. ~~The multifunctional molecule of any one of the claims 76-83, wherein the second antigen binding domain comprises a heavy chain that comprises a HC CDR3 amino acid sequence of **SEQ ID NO: 8055**.~~
85. ~~The multifunctional molecule of any one of the claims 76-84, wherein the second antigen binding domain comprises a heavy chain that comprises a LC CDR3 amino acid sequence of **SEQ ID NO: 8058**.~~
86. ~~An antibody or a binding fragment thereof comprising an antigen binding domain that binds to T cell receptor beta chain constant domain 2 (TRBC2), comprising a heavy chain comprising heavy chain complementarity determining regions (CDRs) HC CDR1, HC CDR2, and HC CDR3 and a light chain, comprising a light chain comprising light chain complementarity determining regions (CDRs) LC CDR1, LC CDR2, and LC CDR3, wherein the HC CDR3 comprises an amino acid sequence of **SEQ ID NO: 8043**.~~

87. ~~An antibody or a binding fragment thereof comprising an antigen-binding domain that binds to T cell-receptor beta chain constant domain 2 (TRBC2) comprising a heavy chain comprising heavy chain complementarity determining regions (CDRs) HC-CDR1, HC-CDR2, and HC-CDR3 and a light chain, comprising a light chain comprising light chain complementarity determining regions (CDRs) LC-CDR1, LC-CDR2, and LC-CDR3, wherein the HC-CDR3 comprises an amino acid sequence of **SEQ ID NO: 8045**.~~
88. ~~An antibody or a binding fragment thereof comprising an antigen-binding domain that binds to T cell-receptor beta chain constant domain 2 (TRBC2) comprising a heavy chain comprising heavy chain complementarity determining regions (CDRs) HC-CDR1, HC-CDR2, and HC-CDR3 and a light chain, comprising a light chain comprising light chain complementarity determining regions (CDRs) LC-CDR1, LC-CDR2, and LC-CDR3, wherein the HC-CDR3 comprises an amino acid sequence of **SEQ ID NO: 8046**.~~
89. ~~An antibody or a binding fragment thereof comprising an antigen-binding domain that binds to T cell-receptor beta chain constant domain 2 (TRBC2) comprising a heavy chain comprising heavy chain complementarity determining regions (CDRs) HC-CDR1, HC-CDR2, and HC-CDR3 and a light chain, comprising a light chain comprising light chain complementarity determining regions (CDRs) LC-CDR1, LC-CDR2, and LC-CDR3, wherein the HC-CDR3 comprises an amino acid sequence of **SEQ ID NO: 8047**.~~
90. ~~The antibody or a binding fragment of any one of the claims 86-89, wherein the HC-CDR1 comprises an amino acid sequence of **SEQ ID NO: 8041**.~~
91. ~~The antibody or a binding fragment of any one of the claims 86-90, wherein the HC-CDR2 comprises an amino acid sequence of **SEQ ID NO: 8042** or **SEQ ID NO: 8044**.~~
92. ~~The antibody or a binding fragment of any one of the claims 86-91, wherein the LC-CDR1 comprises an amino acid sequence of **SEQ ID NO: 8048** or **SEQ ID NO: 8051**.~~
93. ~~The antibody or a binding fragment of any one of the claims 86-89, wherein the LC-CDR2 comprises an amino acid sequence of **SEQ ID NO: 8049**.~~
94. ~~The antibody or a binding fragment of any one of the claims 86-93, wherein the LC-CDR3 comprises an amino acid sequence of **SEQ ID NO: 8050** or **8052**.~~
95. ~~The antibody or a binding fragment of any one of the claims 86-94, wherein the TRBC2 binding domain comprises a heavy chain that is at least 90% identical to **SEQ ID NO: 8011**.~~
96. ~~The antibody or a binding fragment of any one of the claims 86-93, or 95, wherein the TRBC2 binding domain comprises a light chain that is at least 95% identical to **SEQ ID NO: 8012**.~~
97. ~~The antibody or a binding fragment of any one of the claims 86-96, wherein the TRBC2 binding domain comprises an scFv.~~
98. ~~The antibody or a binding fragment of any one of the claims 86-97, further comprising one or more binding domains that binds a different target.~~

- ~~99. The antibody or a binding fragment of claim 98, wherein the antibody is a multispecific antibody.~~
- ~~100. The antibody or a binding fragment of claim 98, wherein the antibody is a bispecific antibody.~~
- ~~101. The multifunctional molecule of any one of the claims 44-85, wherein the molecule binds to a human cell.~~
- ~~102. The multifunctional molecule of claim 101, wherein the molecule binds to a human T cell that expresses NKp30 and TRBC2.~~
- ~~103. The multifunctional molecule of claim 101, wherein the molecule does not bind to a human T cell that does not express TRBC2.~~
- ~~104. A method of treating a cancer, comprising administering to a subject in need thereof a composition comprising the multifunctional molecule of any one of the claims 44-101 or a polynucleotide encoding the same.~~
- ~~105. The method of claim 104, wherein the composition further comprises a cell comprising the polynucleotide encoding the multifunctional molecule of any one of the claims 44-103.~~
- ~~106. The method of claim 104, wherein the cell is a human cell.~~
- ~~107. The method of claim 104 or 105, wherein the cell expresses the multifunctional molecule encoded by the polynucleotide.~~
- ~~108. The method of any one of the claims 104-106, wherein the cancer is a T cell cancer.~~
- ~~109. A multifunctional molecule comprising a heavy chain or a light chain or both selected from any of the sequences of **SEQ ID NO: 8059-8026**.~~
- ~~110. A multi-specific molecule, comprising an anti-TRBC2 Fab-Fc knob chain, having a light chain of **SEQ ID NO: 8281**, a heavy chain sequence of **SEQ ID NO: 8283**; and an anti-NKp30-scFv-Fc hole chain of **SEQ ID NO: 8286**.~~
- ~~111. A multi-specific molecule, comprising an anti-TRBC2 Fab-Fc knob chain, having a light chain of **SEQ ID NO: 8292**, a heavy chain sequence of **SEQ ID NO: 8294**; and an anti-NKp30-scFv-Fc hole chain of **SEQ ID NO: 8286**.~~
- ~~112. A TRBC2 binding molecule, comprising an anti-TRBC2 Fab-Fc knob chain, having a light chain of **SEQ ID NO: 8297**, a heavy chain sequence of **SEQ ID NO: 8298**; and/or an Fc hole chain of **SEQ ID NO: 8300**.~~
- ~~113. A TRBC2 binding molecule, comprising an anti-TRBC2 Fab-Fc knob chain, having a light chain of **SEQ ID NO: 8301**, a heavy chain sequence of **SEQ ID NO: 8302**; and/or an Fc hole chain of **SEQ ID NO: 8300**.~~
- ~~114. A multi-specific molecule, comprising an anti-TRBC1 Fab-Fc knob chain, having a light chain of **SEQ ID NO: 7380**, a heavy chain sequence of **SEQ ID NO: 7382**; and an NKp30-scFv-Fc hole chain of **SEQ ID NO: 8286**.~~

115. ~~An NK-p30 binding molecule, comprising an anti-NKp30 Fab-Fc knob chain, having a light chain of SEQ ID NO: 8301, a heavy chain sequence of SEQ ID NO: 8302; and/or an Fc hole chain of SEQ ID NO: 8300.~~
116. ~~A TRBC1 binding molecule, comprising an anti-NKp30 Fab-Fc knob chain, having a light chain of SEQ ID NO: 8307, a heavy chain sequence of SEQ ID NO: 8309; and/or an Fc hole chain of SEQ ID NO: 8300.~~
117. ~~An antibody or a fragment thereof that binds to a TRBC1 molecule, wherein the antibody or fragment thereof that binds to the TRBC1 comprises a heavy chain comprising an HC-CDR1, having a sequence GYVMH (SEQ ID NO: 8643); an HC-CDR2, having a sequence of FINPYNDDIQSNERFRG (SEQ ID NO: 8644); and an HC-CDR3, having a sequence of GAGYNFDGAYRFFDF (SEQ ID NO: 8645); and a light chain comprising an LC-CDR1 of RSSQRLVHSNGNTYLH (SEQ ID NO: 8646), an LC-CDR2 of RVSNRFP (SEQ ID NO: 8647), an LC-CDR3 of SEQ ID NO: SQSTHVPYT (SEQ ID NO: 8648).~~
118. ~~An antibody or a fragment thereof that binds to a TRBC1 molecule, wherein the antibody or fragment thereof that binds to the TRBC1 comprises a heavy chain comprising an HC-CDR1, having a sequence GYVMH (SEQ ID NO: 8643); an HC-CDR2, having a sequence FHPIFGTANYAQKFQG (SEQ ID NO: 8649) and an HC-CDR3, having a sequence GAGYNFDGAYRFFDF (SEQ ID NO: 8650); and a light chain comprising an LC-CDR1 having a sequence, RSSQRLVHSNGNTYLH (SEQ ID NO: 8651), an LC-CDR2 having sequence RVSNRFP (SEQ ID NO: 8652), and an LC-CDR3 having a sequence SQSTHVPYT (SEQ ID NO: 8653).~~
119. ~~An antibody or a fragment thereof that binds to a TRBC1 molecule, wherein the antibody or fragment thereof that binds to the TRBC1 comprises a heavy chain comprising an HC-CDR1, having a sequence GYVMH (SEQ ID NO: 8643); an HC-CDR2, having a sequence FINPYNDDIQSNERFRG (SEQ ID NO: 8654) and an HC-CDR3, having a sequence GAGYNFDGAYRFFDF (SEQ ID NO: 8655); and a light chain comprising an LC-CDR1 having a sequence, RSSQRLVHSNGNTYLH (SEQ ID NO: 8656), an LC-CDR2 having sequence RVSNRFP (SEQ ID NO: 8657), and an LC-CDR3 having a sequence SQSTHVPYT (SEQ ID NO: 8658).~~
120. ~~An antibody or a fragment thereof that binds to a TRBC1 molecule, wherein the antibody or fragment thereof that binds to the TRBC1 comprises a heavy chain comprising an HC-CDR1, having a sequence GYVMH (SEQ ID NO: 8643); an HC-CDR2, having a sequence FHPIFGTANYAQKFQG (SEQ ID NO: 8659) and an HC-CDR3, having a sequence GAGYNFDGAYRFFDF (SEQ ID NO: 8660); and a light chain comprising an LC-CDR1 having a sequence, RSSQRLVHSNGNTYLH (SEQ ID NO: 8661), an LC-CDR2 having sequence~~

- RVSNRFP (SEQ ID NO: 8662), and an LC CDR3 having a sequence SQSTHVPYT (SEQ ID NO: 8663).
121. ~~An antibody or a fragment thereof that binds to a TRBC1 molecule, wherein the antibody or fragment thereof that binds to the TRBC1 comprises a heavy chain comprising an HC CDR1, having a sequence GYVMH (SEQ ID NO 8643); an HC CDR2, having a sequence FINPYNDIQSNERFRG (SEQ ID NO: 8664) and an HC CDR3, having a sequence GAGYNFDGAYRFFDF (SEQ ID NO: 8665); and a light chain comprising an LC CDR1 having a sequence, RSSQRLVHSNGNTYLH (SEQ ID NO: 8666), an LC CDR2 having sequence RVSNRFP (SEQ ID NO: 8667), and an LC CDR3 having a sequence SQSTHVPYT (SEQ ID NO: 8668).~~
122. ~~A multifunctional molecule, comprising: (i) an anti-TRBC1 antibody or binding fragment thereof comprising a heavy chain comprising an HC CDR1s of SEQ ID NO 8643, or an HC CDR2, having a sequence of SEQ ID NO: 8644, or an HC CDR3 having a sequence of SEQ ID NO: 8645 and a light chain, comprising an LC CDR1 having a sequence of SEQ ID NO: 8646, or an LC CDR2 having sequence of SEQ ID NO: 8647, or an LC CDR3 having a sequence of SEQ ID NO: 8648; and (ii) a second antigen binding domain that binds to NKp30.~~
123. ~~A multifunctional molecule, comprising: (i) an anti-TRBC1 antibody or binding fragment thereof comprising a heavy chain comprising an HC CDR1s of SEQ ID NO 8643, or an HC CDR2, having a sequence of SEQ ID NO: 8649, or an HC CDR3 having a sequence of SEQ ID NO: 8650 and a light chain, comprising an LC CDR1 having a sequence of SEQ ID NO: 8651, or an LC CDR2 having sequence of SEQ ID NO: 8652, or an LC CDR3 having a sequence of SEQ ID NO: 8653; and (ii) a second antigen binding domain that binds to NKp30.~~
124. ~~A multifunctional molecule, comprising: (i) an anti-TRBC1 antibody or binding fragment thereof comprising a heavy chain comprising an HC CDR1s of SEQ ID NO 8643, or an HC CDR2, having a sequence of SEQ ID NO: 8654, or an HC CDR3 having a sequence of SEQ ID NO: 8655, and a light chain, comprising an LC CDR1 having a sequence of SEQ ID NO: 8656, or an LC CDR2 having sequence of SEQ ID NO: 8657, or an LC CDR3 having a sequence 8658; and (ii) a second antigen binding domain that binds to NKp30.~~
125. ~~A multifunctional molecule, comprising: (i) an anti-TRBC1 antibody or binding fragment thereof comprising a heavy chain comprising an HC CDR1s of SEQ ID NO 8643, or an HC CDR2, having a sequence of SEQ ID NO: 8659, or an HC CDR3 having a sequence of SEQ ID NO: 8660, and a light chain, comprising an LC CDR1 having a sequence of SEQ ID NO: 8661, or an LC CDR2 having sequence of SEQ ID NO: 8662, or an LC CDR3 having a sequence 8663; and (ii) a second antigen binding domain that binds to NKp30.~~
126. ~~A multifunctional molecule, comprising: (i) an anti-TRBC1 antibody or binding fragment thereof comprising a heavy chain comprising an HC CDR1s of SEQ ID NO 8643, or an HC CDR2, having~~

~~a sequence of SEQ ID NO: 8664, or an HC CDR3 having a sequence of SEQ ID NO: 8665, and a light chain, comprising an LC CDR1 having a sequence of SEQ ID NO: 8666, or an LC CDR2 having sequence of SEQ ID NO: 8667, or an LC CDR3 having a sequence 8668; and (ii) a second antigen binding domain that binds to NKp30.~~

26. The multifunctional molecule of any one of claims 1-25, wherein the multifunctional molecule comprises the following configuration:

A-, B-[dimerization module]-C, -D,

wherein:

(A) the dimerization module comprises immunoglobulin constant domains;

(B) A, B, C, and D are independently (i) absent; (ii) the first antigen binding domain; (iii) the second antigen binding domain that binds to NKp30; (iv) a cytokine molecule or a cytokine inhibitor molecule; (v) a death receptor signal engager; or (vi) a stromal modifying moiety.

27. The multifunctional molecule of any one of claims 1-26, wherein the multifunctional molecule comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, and wherein:

(1)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8284;

(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8282; and

(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8287;

(2)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8295;

(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8293; and

(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8287;

(3)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8304;

(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 258; and

(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8287;

(4)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7420;

- (ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7419; and
- (iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7302 and a sequence having at least 85% identity to the sequence of SEQ ID NO: 7309;
- (5)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7420;
 - (ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7419; and
 - (iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7311;
- (6)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7423;
 - (ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7419; and
 - (iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7302 and a sequence having at least 85% identity to the sequence of SEQ ID NO: 7309; or
- (7)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7423;
 - (ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7419; and
 - (iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7311.

28. The multifunctional molecule of any one of claims 1-27, wherein the multifunctional molecule comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, and wherein:

- (1)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 8284;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 8282; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 8287;
- (2)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 8295;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 8293; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 8287;
- (3)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 8304;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 258; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 8287;

- (4)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 7420;
(ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 7419; and
(iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7302 and the
sequence of SEQ ID NO: 7309;
- (5)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 7420;
(ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 7419; and
(iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7311;
- (6)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 7423;
(ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 7419; and
(iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7302 and the
sequence of SEQ ID NO: 7309; or
- (7)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 7423;
(ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 7419; and
(iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7311.

29. The multifunctional molecule of any one of claims 1-28, wherein the multifunctional molecule comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, and wherein:

- (1)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the
sequence of SEQ ID NO: 8283;
(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the
sequence of SEQ ID NO: 8281; and
(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the
sequence of SEQ ID NO: 8286;
- (2)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the
sequence of SEQ ID NO: 8294;
(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the
sequence of SEQ ID NO: 8292; and
(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the
sequence of SEQ ID NO: 8286;
- (3)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the
sequence of SEQ ID NO: 7382;
(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the
sequence of SEQ ID NO: 7380; and
(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the
sequence of SEQ ID NO: 8286;
- (4)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the

sequence of SEQ ID NO: 7438;

(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7439; and

(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7383;

(5)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7440;

(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7439; and

(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7383;

(6)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8001;

(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8002; and

(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7383;

(7)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8004;

(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8005; and

(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7383;

(8)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8007;

(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8008; and

(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7384; or

(9)(i) the first polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8009;

(ii) the second polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 8010; and

(iii) the third polypeptide chain comprises a sequence having at least 85% identity to the sequence of SEQ ID NO: 7384.

30. The multifunctional molecule of any one of claims 1-29, wherein the multifunctional molecule comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, and wherein:

- (1)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 8283;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 8281; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 8286;
- (2)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 8294;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 8292; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 8286;
- (3)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 7382;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 7380; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 8286;
- (4)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 7438;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 7439; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7383;
- (5)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 7440;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 7439; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7383;
- (6)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 8001;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 8002; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7383;
- (7)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 8004;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 8005; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7383;
- (8)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 8007;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 8008; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7384; or
- (9)(i) the first polypeptide chain comprises the sequence of SEQ ID NO: 8009;
 - (ii) the second polypeptide chain comprises the sequence of SEQ ID NO: 8010; and
 - (iii) the third polypeptide chain comprises the sequence of SEQ ID NO: 7384.

31. A polynucleotide comprising a sequence encoding the multifunctional molecule of any one of claims 1-30.

32. A pharmaceutical composition comprising the multifunctional molecule of any one of claims 1-30, and a pharmaceutically acceptable carrier, excipient, or stabilizer for use in therapy.

33. Use of a pharmaceutical composition comprising the multifunctional molecule of any one of claims 1-30 in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein the pharmaceutical composition comprises an effective amount of the multifunctional molecule.

34. The use of claim 33, wherein the cancer is a T cell cancer, or the cancer is leukemia or lymphoma.

35. The use of claim 33 or 34, wherein the cancer is selected from the group consisting of Acquired immune deficiency syndrome (AIDS)-associated lymphoma, Angioimmunoblastic T-cell lymphoma, Adult T-cell leukemia/lymphoma, Burkitt lymphoma, Central nervous system (CNS) lymphoma, Diffuse large B-cell lymphoma (DLBCL), Lymphoblastic lymphoma, Mantle cell lymphoma (MCL), Peripheral T-cell lymphoma (PTCL), Transformed follicular and transformed mucosa-associated lymphoid tissue (MALT) lymphomas, Cutaneous T-cell lymphoma, Follicular lymphoma, Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, Marginal zone B-cell lymphoma, Gastric mucosa-associated lymphoid tissue (MALT) lymphoma, Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL), Extranodal T-/NK-cell lymphoma, and Anaplastic large-cell lymphoma; and optionally, wherein the cancer is Peripheral T-cell lymphoma (PTCL).

36. The use of claim 35, wherein:

(i) the peripheral T-cell lymphoma (PTCL) is Hepatosplenic T-cell lymphoma (HSGDTCL),

Subcutaneous panniculitis-like T-cell lymphoma, or Enteropathy-associated T-cell lymphoma;

(ii) the cutaneous T-cell lymphoma is mycosis fungoides and Sézary syndrome;

(iii) the extranodal T-/NK-cell lymphoma is a nasal type; and/or

(iv) the anaplastic large-cell lymphoma is primary cutaneous anaplastic large-cell lymphoma or systemic anaplastic large-cell lymphoma.